As
filed with the U.S. Securities and Exchange Commission on January 20, 2023.
Registration
Statement No. 333-268932
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
S-3/A
(AMENDMENT NO. 1)
REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933
Summit
Therapeutics Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
37-1979717 |
(State
or other jurisdiction of incorporation
or organization) |
|
(I.R.S.
Employer Identification Number) |
2882
Sand Hill Road, Suite 106
Menlo
Park, CA 94025
(617)
514-7149
(Address,
including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
Robert
Duggan |
Mahkam
Zanganeh |
Chairman and Chief
Executive Officer |
Co-Chief Executive
Officer and President |
Summit Therapeutics
Inc. |
Summit Therapeutics
Inc. |
2882 Sand Hill
Road, Suite 106 |
2882 Sand Hill
Road, Suite 106 |
Menlo Park, CA
94025 |
Menlo Park, CA
94025 |
(617) 514-7149 |
(617) 514-7149 |
(Name,
address, including zip code, and telephone number, including area code, of agent for service)
With
copies to:
Adam
Finerman, Esq.
Baker
& Hostetler LLP
45
Rockefeller Plaza
New
York, NY 10111
Tel:
(212) 589-4233
Approximate
date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.
If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please
check the following box: ☐
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check
the following box check the following box: ☐
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please
check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box. ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
Non-accelerated
filer |
☒ |
Smaller
reporting company |
☒ |
|
|
Emerging
growth company |
☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
☐
The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until
the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become
effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become
effective on such date as the Commission acting pursuant to said Section 8(a), may determine.
The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we
are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.
PRELIMINARY
PROSPECTUS SUBJECT TO COMPLETION, DATED JANUARY 20, 2023
PROSPECTUS
SUMMIT
THERAPEUTICS INC.
Subscription
Rights to Purchase Up to 476,190,476 Shares of Common Stock at the Initial Price
Summit
Therapeutics Inc. is distributing at no charge to the holders of our common stock, par value $0.01 per share, non-transferable
subscription rights (each, a “Subscription Right”) to purchase up to 476,190,476 shares of common stock (the “Rights
Offering”) at the Initial Price (as defined below) with an aggregate offering value of up to $500,000,000. The subscription
price per share of common stock shall be equal to the lesser of (i) $1.05 (the “Initial Price”) and (ii) the volume
weighted-average price of our common stock for the preceding five-day trading period through and including the Expiration Date
(as defined below) (the “Alternate Price”), as provided herein. Each stockholder will receive one Subscription Right
entitling the holder to purchase 2.152353 shares of common stock at the Initial Price (the “Basic Subscription Right”),
for each share of our common stock owned at 4:00 p.m., Eastern Time, on [●] (the “Record Date”). To the
extent that the Alternate Price is lower than the Initial Price, we will sell additional shares of common stock in the Rights
Offering, provided that we will not issue any fractional shares of common stock. For a more detailed discussion, see “Rights
Offering —Subscription Rights — Basic Subscription Rights” beginning on page 40. The Initial Price or Alternate
Price, as applicable, is sometimes referred to herein as the “Subscription Price”. The Subscription Price may present
a significant discount to the recent closing trading price of $4.23 on January 19, 2023. Following the closing of the Rights
Offering, there is no assurance that the price will remain at the current trading price, and the price may decline to the Subscription
Price, or to a price lower than the Subscription Price. For a more detailed discussion, see “Dilution” beginning
on page 37. If the Rights Offering is not fully subscribed and you fully exercise your Basic Subscription Right, you may also
exercise your Subscription Rights to purchase additional shares of common stock at the Subscription Price that were not subscribed
for by other Subscription Rights holders under the Rights Offering (the “Over-Subscription Right”), subject to the
availability and pro rata allocation of shares among persons exercising this Over-Subscription Right. However, we will not issue
shares in excess of the total amount authorized by our Board of Directors. For a more detailed discussion, see “Rights
Offering” beginning on page 40.
The
purpose of this Rights Offering is to raise equity capital in a cost-effective manner that provides all of our existing stockholders
the opportunity to participate. The net proceeds will be used for one or more of the following purposes: (i) the repayment to
Robert W. Duggan, the Company’s Chief Executive Officer, Chairman of the Board, and
beneficial owner of approximately 78.1% of the Company’s common stock and Dr. Mahkam Zanganeh, the Company’s co-Chief
Executive Officer, President, member of the Board and beneficial owner of approximately 6.0% of the Company’s common stock,
of certain unsecured promissory notes totaling $420 million issued pursuant to the Note Purchase Agreement and (ii) general
corporate purposes, which includes funding the Company’s activities to support clinical
development and regulatory approval for ivonescimab (also referred to herein as SMT112) and pursue business development opportunities
to expand or enhance our pipeline of drug candidates. For a more detailed discussion, see “Use of Proceeds”
beginning on page 35.
On
December 5, 2022, we entered into a Collaboration and License Agreement (the “License Agreement”) with Akeso, Inc. and
its affiliates (“Akeso”) and certain ancillary transaction documents as set forth
in the License Agreement. The License Agreement was subject to customary closing conditions, including applicable waiting
periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”). Pursuant to the terms of the
License Agreement, we are obligated to make an upfront payment of $500 million, $300 million
of which is payable within the later of 15 days after execution of the License Agreement or upon the earliest date on which
the parties have actual knowledge that all applicable waiting periods under the HSR Act and any comparable extension periods with
respect to the transactions contemplated by the License Agreement have expired or been terminated (the “Antitrust Clearance
Date”) and $200 million of which is payable upon the later of (i) 90 days after the
execution of the License Agreement or (ii) the Antitrust Clearance Date. In connection with the first payment, Akeso may elect to
receive up to 16 million shares of Company common stock in lieu of cash. Following the Antitrust Clearance Date, on January
17, 2023 the License Agreement closed and Akeso was issued 10 million shares of Company common stock and was paid $274.9 million
dollars in cash. The $200 million remaining amount of the $500 million upfront payment is payable March 5, 2023. For a more detailed
discussion, see “Prospectus Summary” beginning on page 18.
On
December 6, 2022, we entered into a Note Purchase Agreement (the “Note Purchase Agreement”)
and promissory notes with Robert W. Duggan, the Company’s Chief Executive Officer, Chairman of the Board, and beneficial
owner of approximately 78.1% of the Company’s common stock and Dr. Mahkam Zanganeh, the Company’s co-Chief Executive
Officer, President, member of the Board and beneficial owner of approximately 6.0% of the Company’s common stock. Pursuant
to the Note Purchase Agreement, the Company agreed to sell to Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate
amount of $520 million for the principal purpose of funding the Company’s initial payment obligations under the License
Agreement. These unsecured promissory notes will be repaid, in part, with the proceeds of this Rights Offering. For a more detailed
discussion, see “Prospectus Summary — Other Material Agreements” beginning on page 21.
The
Subscription Rights will be distributed and exercisable beginning on the date of this prospectus. The Subscription Rights will
expire and will have no value if they are not exercised prior to the expiration date of this Rights Offering, which is currently
expected to be 5:00 p.m. Eastern Time, on [●] (the “Expiration Date”), unless we, in our sole discretion,
extend the period for exercising the Subscription Rights. We will extend the duration of the Rights Offering as required by applicable
law and may choose to extend the Rights Offering if we decide that changes in the market price of our common stock warrant an
extension or if we decide that the degree of participation in this Rights Offering by holders of our common stock is less than
the level we desire. You should carefully consider whether or not to exercise your Subscription Rights before the Expiration Date.
We reserve the right to cancel the Rights Offering at any time before the expiration of the Rights Offering, for any reason.
Robert
W. Duggan, our Executive Chairman, Chief Executive Officer, and the beneficial owner of approximately 78.1% of our common stock
prior to this Rights Offering, and Dr. Mahkam Zanganeh, our co-Chief Executive Officer, President, a member of our Board of Directors,
and the beneficial owner of approximately 6.0% of our common stock prior to this Rights Offering, have each indicated that they
intend to participate in the Rights Offering and subscribe for at least the full amount of their Basic Subscription Rights, but
have not made any formal binding commitment to participate.
There
is no minimum number of shares of common stock that we must sell in order to complete the Rights Offering. If the Rights Offering
is not fully subscribed and you fully exercise your Basic Subscription Right, you may also exercise your Over-Subscription Right,
subject to the availability and pro rata allocation of shares among persons exercising this Over-Subscription Right. Stockholders
who do not participate in the Rights Offering will continue to own the same number of shares, but will own a smaller percentage
of the total shares outstanding after the Rights Offering to the extent that other stockholders participate in the Rights Offering.
Rights that are not exercised by the Expiration Date will expire and have no value.
We
are distributing the rights and offering the underlying securities directly to you. We have not employed any brokers, dealers
or underwriters in connection with the solicitation or exercise of rights in the Rights Offering and no commissions, fees or discounts
will be paid in connection with the Rights Offering. Broadridge Corporate Issuer Solutions, LLC is acting as the subscription
agent and information agent for the Rights Offering. While certain of our directors, officers and other employees may solicit
responses from you, those directors, officers and other employees will not receive any commissions or compensation for their services
other than their normal compensation.
If
you want to participate in this Rights Offering and you are the record holder of your shares, we recommend that you submit your
subscription documents to the Subscription Agent well before the deadline. If you want to participate in this Rights Offering
and you hold shares through your broker, dealer, bank, or other nominee, you should promptly contact your broker, dealer, bank,
or other nominee and submit your subscription documents in accordance with the instructions and within the time period provided
by your broker, dealer, bank, or other nominee.
The
Subscription Rights may not be sold or transferred except as required by operation of law and will not be listed for trading on
NASDAQ or any other stock exchange or market. You are urged to obtain a current price quote for our common stock before exercising
your Subscription Rights.
Our
common stock is listed on the Nasdaq Global Market under the symbol “SMMT”. On January 19, 2023, the last reported sales
price of our common stock was $4.23.
There
is no minimum amount of proceeds necessary in order for us to close the Rights Offering.
Investing
in our securities involves a high degree of risk. See “Risk Factors” beginning on page 23 of this prospectus
and page 41 of our Annual Report on Form 10-K for the year ended December 31, 2021, incorporated by reference herein as
well as the other information contained in this prospectus and the documents incorporated by reference in this prospectus
or in any accompanying prospectus supplement for a discussion of the factors you should carefully consider before
making a decision to invest in our securities.
Our
board of directors, or the Board, reserves the right to terminate the Rights Offering for any reason at any time before the
completion of the Rights Offering. If we terminate the Rights Offering, all subscription payments received will be returned as soon
as practicable, without interest or penalty.
The
Board is making no recommendations regarding your exercise of the Subscription Rights. You should carefully consider whether to
exercise your Subscription Rights before the Expiration Date. You may not revoke or revise any exercises of Subscription Rights
once made, unless we terminate the Rights Offering.
You
should rely only on the information contained in this prospectus or any prospectus supplement or amendment hereto. We have not
authorized anyone to provide you with different information.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The
date of this prospectus is [●]
Table
of Contents
Page
ABOUT
THIS PROSPECTUS
This
prospectus is part of a registration statement on Form S-3 that we filed with the United States Securities and Exchange Commission
(the “SEC”). Under this registration statement, we may distribute non-transferable subscription rights (the “Subscription
Rights”) to purchase up to 476,190,476 of shares of our common stock (the “Rights Offering”).
You
should read this prospectus, the documents incorporated by reference into this prospectus, and any prospectus supplement or free
writing prospectus that we may authorize for use in connection with this Rights Offering in their entirety before making an investment
decision. You should also read and consider the information in the documents to which we have referred you in the sections of
this prospectus entitled “Incorporation of Certain Information by Reference” beginning on page 53 and “Where
You Can Find More Information” beginning on page 54. These documents contain important information that you should consider
when making your investment decision.
You
should only rely on the information contained in, or incorporated by reference into, this prospectus, in any prospectus supplement
or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We have not authorized anyone
to provide any information other than that contained in this prospectus, in any prospectus supplement or in any free writing prospectus
prepared by or on behalf of us or to which we have referred you. We are offering to sell, and seeking offers to buy, securities
only in jurisdictions where such offers and sales are permitted. The information in this prospectus, in any prospectus supplement
or any free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of securities.
Our business, financial condition, results of operations and prospects may have changed since that date.
Unless
otherwise indicated, information contained in, or incorporated by reference into, this prospectus concerning our industry and
the markets in which we operate, including our general expectations and market position, market opportunity and market share,
is based on information from our own management estimates and research, as well as from industry and general publications and
research, surveys and studies conducted by third parties. Management estimates are derived from publicly available information,
our knowledge of our industry and assumptions based on such information and knowledge, which we believe to be reasonable. In addition,
assumptions and estimates of our and our industry’s future performance are necessarily subject to a high degree of uncertainty
and risk due to a variety of factors, see “Risk Factors” beginning on page 23. These and other factors could
cause our future performance to differ materially from our assumptions and estimates. See “Cautionary Note Regarding
Forward-Looking Statements” beginning on page 1.
Except
as otherwise indicated herein or as the context otherwise requires, references in this prospectus to “Summit,” the
“Company,” “we,” “us,” “our” and similar references refer to Summit Therapeutics
Inc., a Delaware corporation, and its consolidated subsidiaries.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
Some
of the statements made under “Prospectus Summary,” “Risk Factors,” “Use of Proceeds,”
and elsewhere in this prospectus and the documents incorporated by reference herein, including in our Annual Report on Form 10-K
for the fiscal year ended December 31, 2021 and other documents incorporated by reference into this prospectus, constitute forward-looking
statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,”
“should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,”
“predicts,” “potential” “intends” or “continue,” or the negative of these terms
or other comparable terminology.
These
forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements
that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements relating
to the research, development, completion and use of our products, and all statements (other than statements of historical facts)
that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the
future.
Forward-looking
statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking
statements on assumptions and assessments made by our management in light of their experience and their perception of historical
trends, current conditions, expected future developments and other factors they believe to be appropriate.
Important
factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these
forward-looking statements include, among others, those factors referred to in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2021, and Quarterly Reports on Form 10-Q filed thereafter, which are incorporated by reference herein.
These
statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may
cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from
those anticipated by the forward-looking statements. We discuss many of these risks in this prospectus in greater detail under
the heading “Risk Factors” and other risk factors contained in the documents incorporated by reference herein.
You should not rely upon forward-looking statements as predictions of future events.
Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the
forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this prospectus.
SUMMARY OF THE RIGHTS OFFERING
Securities
to be Offered: |
We
are distributing to you, at no charge, one non-transferable Subscription Right (each,
a “Right”) to purchase 2.152353 shares of our common stock at the Initial
Price for every one share of our common stock that you owned as of 4:00 p.m., Eastern
Time, on [●], either as a holder of record or, in the case of shares held of record
by custodian banks, brokers, dealers or other nominees on your behalf, as a beneficial
owner of such shares. Subscription Rights will be rounded down to the nearest whole number
and, accordingly, no fractional Subscription Rights will be issued. To the extent that
the Alternate Price (as defined below) is lower than the Initial Price, we will sell
additional shares of common stock.
The
shares of common stock sold in this Rights Offering will be issued only in book-entry form. The Subscription Rights will not be
transferable and will not trade as a separate security on any trading market. |
Subscription
Price: |
The
subscription price per share of common stock will be the lesser of (i) $1.05 (the “Initial
Price”) and (ii) the volume weighted-average price of the common stock for the
preceding five consecutive trading days through and including the Expiration Date (as
defined below) (the “Alternate Price”). The Initial Price or Alternate Price,
as applicable, is sometimes referred to herein as the “Subscription Price”.
The Subscription Price may present a significant discount to the recent closing trading
price of $4.23 on January 19, 2023. Following the closing of the Rights Offering,
there is no assurance that the price will remain at the current trading price, and the
price may decline to the Subscription Price, or to a price lower than the Subscription
Price. For a more detailed discussion, see “Dilution” beginning on
page 37. Prior to the Expiration Date, subscribers must fund their subscriptions pursuant
to both the Basic Subscription Right and Over-Subscription Right at the Initial Price.
To be effective, any payment related to the exercise of a right must clear prior to the
expiration of the Rights Offering.
|
Record
Date: |
[●]
(the “Record Date”)
|
Basic
Subscription Rights: |
Each
Subscription Right will entitle the holder to purchase 2.152353 shares of common stock
at the Initial Price (the “Basic Subscription Right”) which shall be paid
in cash. To the extent that the Alternate Price is lower than the Initial Price, we will
sell additional shares of common stock.
|
Over-Subscription
Rights: |
We
do not expect that all of our stockholders will exercise all of their Basic Subscription Rights. If you fully exercise your Basic
Subscription Right and other stockholders do not fully exercise their Basic Subscription Rights, you may also exercise your Subscription
Rights to purchase at the Subscription Price common stock that were not subscribed for by other Subscription Rights holders under
the Rights Offering (the “Over-Subscription Right”), subject to the availability and pro rata allocation of shares
among persons exercising this Over-Subscription Right. If an insufficient number of shares of common stock are available to fully
satisfy all proper Over-Subscription Right requests, the available shares of common stock issuable in this Rights Offering will
be distributed proportionately among Subscription Rights holders who properly exercise their Over-Subscription Right based on
the number of shares of common stock each Subscription Rights holder timely subscribed and paid for under the Basic Subscription
Right. The proration process will be repeated until all shares of common stock have been allocated or all properly made Over-Subscription
Right exercises have been fulfilled, whichever occurs earlier. |
Expiration
Date: |
The
Subscription Rights will expire at 5:00 PM Eastern Time, on [●] (the “Expiration
Date”). We reserve the right to extend the Expiration Date in our sole discretion.
|
Excess
Subscription Amount |
If,
on the Expiration Date, the Alternate Price is lower than the Initial Price, any excess
subscription amounts paid by a subscriber (the “Excess Subscription Amount”)
will be allocated towards the purchase of additional shares of common stock. For more
information, see “Questions and Answers About the Rights Offering”.
|
Purchase
Commitments |
Robert
W. Duggan, our Executive Chairman, Chief Executive Officer, and the beneficial owner
of approximately 78.1% of our common stock prior to this Rights Offering, and Dr. Mahkam
Zanganeh, our co-Chief Executive Officer, President, a member of our Board of Directors,
and the beneficial owner of approximately 6.0% of our common stock prior to this Rights
Offering, have each indicated that they intend to participate in the Rights Offering
and subscribe for at least the full amount of their Basic Subscription Rights, but have
not made any formal binding commitment to participate.
|
Procedure
for Exercising Subscription Rights: |
You
may exercise your Subscription Rights by properly completing and executing your rights
certificate and delivering it, together with the Subscription Price for each share of
common stock for which you subscribe under the Basic Subscription Right and Over-Subscription
Right, to the subscription agent, Broadridge Corporate Issuer Solutions, LLC, on or prior
to the Expiration Date. If you use mail, we recommend that you use insured, registered
mail, with return receipt requested.
|
How
Subscription Rights Holders Can Exercise Rights Through Others |
If
you hold our common stock through a custodian bank, broker, dealer, or other nominee,
we will ask your custodian bank, broker, dealer or other nominee to notify you of the
Rights Offering. If you wish to exercise your Subscription Rights, you will need to have
your custodian bank, broker, dealer or other nominee act for you. To indicate your decision,
you should complete and return to your custodian bank, broker, dealer or other nominee
the form entitled “Beneficial Owners Election Form.” You should receive this
form from your custodian bank, broker, dealer or other nominee with the other Rights
Offering materials. You should contact your custodian bank, broker, dealer or other nominee
if you believe you are entitled to participate in the Rights Offering but you have not
received this form.
|
How
Foreign Stockholders and Other Stockholders Can Exercise Rights |
The
subscription agent will not mail rights certificates to you if you are a registered stockholder
whose address is outside the United States or if you have an Army Post Office or a Fleet
Post Office address. Instead, we will have the subscription agent hold the Subscription
Rights certificates for your account. To exercise your Subscription Rights, you must
notify the subscription agent prior to 11:00 a.m., Eastern Time, at least three (3) business
days prior to the Expiration Date, and establish to the satisfaction of the subscription
agent that it is permitted to exercise your Subscription Rights under applicable law.
If you do not follow these procedures by such time, your Subscription Rights will expire
and will have no value. If you hold your shares in the name of a custodian bank, broker,
dealer or other nominee, you should follow the instructions you receive from it, as described
above.
|
No
Fractional Shares |
We
will not sell fractional shares of common stock but rather will round down the aggregate
number of shares of common stock you are entitled to receive to the nearest whole number.
For more information about how the number of shares of common stock is computed, see
“Questions and Answers About the Rights Offering — What happens if the
final Subscription Price is less than the Initial Price?”
Any
Excess Subscription Amount resulting from the reduction of the Subscription Price from the Initial Price to the Alternate
Price will be allocated towards the purchase of additional shares of common stock (either towards your Basic Subscription
Right, if available, or towards the Over-Subscription Right if you have already exercised your Basic Subscription Right
in full). The excess amount for any fractional shares will be returned to you as soon as practicable, in the form in which
made. You will not receive interest or a deduction on any payments refunded to you under the Rights Offering.
|
Payment
Adjustments |
If
you send a payment that is insufficient to purchase the number of shares of common stock
requested, or if the number of shares of common stock requested is not specified in the
rights certificate, the payment received will be applied to exercise your Subscription
Rights to the extent of the payment. If the payment exceeds the amount necessary for
the full exercise of your Subscription Rights, including any Over-Subscription Rights
exercised and permitted and, on the Expiration Date, the Alternate Price is lower than
the Initial Price, any Excess Subscription Amount will be allocated towards the purchase
of additional shares of common stock (either towards your Basic Subscription Right, if
available, or towards the Over-Subscription Right if you have already exercised your
Basic Subscription Right in full). Otherwise, the excess will be returned to you as soon
as practicable, in the form in which made. You will not receive interest or a deduction
on any payments refunded to you under the Rights Offering.
|
Conditions |
See
“The Rights Offering — Conditions to the Rights Offering” beginning
on page 40.
|
Delivery
of Shares: |
As
soon as practicable after the expiration of the Rights Offering, the subscription agent
will arrange for the issuance of the shares of common stock received pursuant to the
Rights Offering. All shares that are purchased in the Rights Offering will be issued
in book-entry, or uncertificated, form meaning that you will receive a direct registration
(DRS) account statement from our transfer agent reflecting ownership of these securities
if you are a holder of record of shares. If you hold your shares in the name of a custodian
bank, broker, dealer, or other nominee, the Depository Trust Company (DTC) will credit
your account with your nominee with the securities you purchased in the Rights Offering.
|
Non-transferability
of Subscription Rights: |
The
Subscription Rights may not be sold, transferred or assigned and will not be listed for
trading on the Nasdaq Global Market or any other stock exchange or trading market.
|
No
Recommendation to Subscription Rights Holders: |
Although
certain of our directors may be investing their own money in the Rights Offering, our
board of directors is making no recommendation regarding your exercise of the Subscription
Rights. You are urged to make your decision based on your own assessment of our business
and the Rights Offering. An investment in shares of common stock must be made according
to your evaluation of your own best interests and after considering all of the information
herein, including the section titled “Risk Factors” beginning on page
23 of this prospectus. Neither we nor our board of directors are making any recommendation
regarding whether you should exercise your Subscription Rights.
|
No
Revocation: |
Once
you submit the form of rights certificate to exercise any Subscription Rights, you may
not revoke or change your exercise or request a refund of monies paid. All exercises
of rights are irrevocable, even if you subsequently learn information about us that you
consider to be unfavorable. You should not exercise your Subscription Rights unless you
are certain that you wish to purchase shares of common stock in the Rights Offering.
|
Use
of Proceeds: |
Although
we cannot determine what the actual net proceeds from the sale of common stock in the Rights Offering will be until the Rights
Offering is completed, assuming all Subscription Rights are exercised, we estimate that the aggregate net proceeds from the
Rights Offering, after deducting estimated offering expenses, will be approximately $499.5 million. We currently intend
to use the net proceeds for one or more of the following purposes: (i) the repayment of certain unsecured promissory notes
totaling $420 million issued pursuant to the Note Purchase Agreement (as defined in “Prospectus
Summary — Other Material Agreements” beginning
on page 21) and (ii) general corporate purposes, which includes funding the Company’s activities
to support clinical development and regulatory approval for ivonescimab (also referred to herein as SMT112) and pursue business
development opportunities to expand or enhance our pipeline of drug candidates. The
Company expects to use the proceeds of the Note Purchase Agreement to support (1) payment of the upfront obligation totaling
$500 million associated with the License Agreement (as defined in “Prospectus Summary — Collaboration
and License Agreement” beginning on page 19) as described herein; (2)
activities to support clinical development and regulatory approval for SMT112; (3) pursue business development opportunities
to expand or enhance our pipeline of drug candidates; and (4) general corporate purposes. For a more detailed discussion,
see “Use of Proceeds” beginning on page 35. |
Material
U.S. Federal Income Tax Consequences: |
Although
the authorities governing transactions such as this Rights Offering are complex and unclear
in certain respects, we believe and intend to take the position that the distribution
of Subscription Rights to you with respect to your shares of common stock generally should
be treated, for U.S. federal income tax purposes, as a non-taxable distribution if you
are a U.S. taxpayer. For a more detailed discussion, see “Material U.S. Federal
Income Tax Consequences” beginning on page 48. You should consult your tax
advisor as to the particular consequences to you of the Rights Offering.
|
Extension
and Termination: |
We
have the option, exercisable in our sole discretion, to extend the Rights Offering and
the period for exercising your Subscription Rights, although we do not presently intend
to do so. The board of directors, in its sole discretion, reserves the right to amend
or modify the terms of the Rights Offering. We also reserve the right to terminate the
Rights Offering at any time prior to the Expiration Date for any reason, in which event
all funds received in connection with the Rights Offering will be returned without interest
or deduction to those persons who exercised their Subscription Rights.
|
Subscription
Agent: |
Broadridge
Corporate Issuer Solutions, LLC |
Questions: |
You
should direct any questions or requests for assistance concerning the method of subscribing
for shares of common stock or for additional copies of this prospectus the information
agent, Broadridge Corporate Issuer Solutions, LLC, toll free at 1-855-793-5068, by e-mail
at shareholder@broadridge.com, or by mail at:
Broadridge
Corporate Issuer Solutions, LLC
P.O.
Box 1317
Attn:
BCIS Re-Organization Dept.
Brentwood,
NY 11717-0718
|
Market
for Common Stock: |
Our
common stock is listed on the Nasdaq Global Market under the symbol “SMMT.”
The shares of common stock to be issued in connection with the Rights Offering will also
be listed on the Nasdaq Global Market under the same symbol. The Subscription Rights
will not be listed for trading on the Nasdaq Global Market or any other stock exchange
or market.
|
Fees
and Expenses |
We
are not charging any fee or sales commission to issue Subscription Rights to you or to sell common stock to you if you exercise
your Subscription Rights (other than the Subscription Price). If you exercise your Subscription Rights through a custodian bank,
broker, dealer or other nominee, you are responsible for paying any fees your nominee may charge you. |
Risk
Factors: |
Before
you exercise your Subscription Rights to purchase shares, you should be aware that there
are risks associated with your investment, and you should carefully read and consider
risks described herein, see “Risk Factors” beginning on page 23, together
with all of the other information included and incorporated by reference in this prospectus.
|
No
“Going Private” Transaction |
The
Rights Offering is not a transaction or series of transactions which has either a reasonable
likelihood or a purpose of producing a “going private effect” as specified
in Rule 13e-3 of the Exchange Act.
|
Important
Dates to Remember: |
Set
forth below are certain important dates for this Rights Offering, which are generally
subject to extension:
Record
Date: [●]
Expiration
Date: [●]
Deadline
for Delivery of Subscription Rights Statements and Payment for Shares: [●]
Anticipated
Delivery of Shares Purchased in Rights Offering: [●] |
QUESTIONS
AND ANSWERS RELATING TO THE RIGHTS OFFERING
The
following are examples of what we anticipate will be common questions about the Rights Offering. The answers are based on selected
information included elsewhere in this prospectus. The following questions and answers do not contain all of the information that
may be important to you and may not address all of the questions that you may have about the Rights Offering. This prospectus
and the documents incorporated by reference into this prospectus contain more detailed descriptions of the terms and conditions
of the Rights Offering and provide additional information about us and our business, including potential risks related to the
Rights Offering, the shares offered hereby, and our business. We urge you to read this entire prospectus and the documents incorporated
by reference into this prospectus.
Q: |
What
is the Rights Offering? |
A: |
We
are distributing to you, at no charge, one Right to purchase 2.152353 shares of common stock at the Initial Price for every
share of our common stock that you owned as of 4:00 p.m., Eastern Time, on [●], either as a holder of record or, in
the case of shares held of record by custodian banks, brokers, dealers or other nominees on your behalf, as a beneficial owner
of such shares. |
Q: |
Why
are we conducting the Rights Offering? |
A: |
The
purpose of this Rights Offering is to raise equity capital in a cost-effective manner that provides all of our existing stockholders
the opportunity to participate. We currently intend to use the net proceeds for one or more of the following purposes: (i)
the repayment of certain unsecured promissory notes totaling $420 million issued pursuant to the Note Purchase Agreement and
(ii) general corporate purposes, which includes funding the Company’s activities
to support clinical development and regulatory approval for SMT112 and pursue business development opportunities to expand
or enhance our pipeline of drug candidates. For a more detailed discussion, see “Use of Proceeds”
beginning on page 35. |
Q: |
Will
fractional Subscription Rights be issued? |
A: |
No.
As we will not sell fractional shares of common stock, and each Subscription Right represents the right to purchase 2.152353
shares of common stock. Subscription Rights holders will only be entitled to purchase a whole number of shares of common
stock, rounded down to the nearest whole number of shares of common stock a holder would otherwise be entitled to purchase.
For example, if you owned 1,000 shares of our common stock on the Record Date, you would be granted Subscription Rights
to purchase an aggregate of 2,152 shares of common stock (rounded down to the nearest whole share as described herein)
at the Initial Price. If you are entitled to receive a fraction of a share, we will round down the number of shares to
which you are entitled to purchase to the nearest whole number.
Any
Excess Subscription Amount resulting from the reduction of the Subscription Price from the Initial Price to the Alternate
Price will be allocated towards the purchase of additional shares of common stock (either towards your Basic Subscription
Right, if available, or towards the Over-Subscription Right if you have already exercised your Basic Subscription Right
in full). The excess amount for any fractional shares of common stock will be returned to you as soon as practicable,
in the form in which made. You will not receive interest or a deduction on any payments refunded to you under the Rights
Offering.
|
Q: |
How
was the Subscription Price determined? |
A: |
In
determining the Subscription Price, a special committee of independent directors consisting of Manmeet Soni, Ujwala Mahatme and Dr.
Robert Booth (the “Special Committee”) considered a number of factors, including: the likely cost of capital from other
sources and general conditions of the securities markets, the price at which our stockholders might be willing to participate in the
Rights Offering, our need for liquidity and capital, the average price for the 30-day period prior to the filing of the preliminary
Proxy Statement (as defined below) on November 29, 2022, and the desire to provide an opportunity to our stockholders to participate
in the Rights Offering on a pro rata basis. The Special Committee determined that it was in the best interests of the
Company’s stockholders to publicly announce the Initial Price and the Alternate Price so that all stockholders had the
opportunity to determine whether to buy or sell the Company’s shares of common stock prior to the Record Date. The Company did
not consider revising the Initial Price. The Company believes this disclosure has provided its stockholders and the public with
sufficient information about the Company’s expectation to sell a significant number of shares in the Rights Offering, as
described herein. The Subscription Price is not necessarily related to our book value, net worth or any other established criteria
of value and may or may not be considered the fair value of the common stock to be offered in the Rights Offering. You should not
consider the Subscription Price as an indication of value of us or our common stock. The market price of our common stock may
decline during or after the Rights Offering, including below the Subscription Price for the common stock. You should obtain a
current quote for our common stock before exercising your Subscription Rights and make your own assessment of our business and
financial condition, our prospects for the future, and the terms of the Rights Offering. |
Q: |
Why
did our board of directors elect to price the Rights Offering at the lesser of the Initial Price and the Alternate Price? |
A: |
The
Special Committee elected to price the Rights Offering at the lesser of the Initial Price and the Alternate Price to attempt
to protect stockholders from any decline in the price of the Company’s common stock, which may occur after the commencement
of the Rights Offering and prior to the Expiration Date. While there is no guarantee that this mechanism will sufficiently
protect stockholders that exercise their rights (see “Risk Factors” below), our board of directors and
management wanted to encourage participation in the Rights Offering and strike what they believe to be a fair balance between
the capital needs of the Company and the fair value of the common stock to be sold to the stockholders in this Rights Offering. |
Q: |
Because
the final Subscription Price may not be determined until the Expiration Date, how much money should I send to the subscription
agent if I want to exercise my Subscription Rights? |
A: |
For
purposes of initially exercising your Subscription Rights, you should assume that the Subscription Price will equal the Initial
Price of $1.05 per share. Accordingly, for each right that you would like to exercise, including any rights that you would
like the opportunity to exercise pursuant to the Over-Subscription Right, you should send $1.05 per share, noting that each
Subscription Right corresponds to 2.152353 shares of common stock at the Initial Price. For assistance you may contact the
information agent, Broadridge Corporate Issuer Solutions, LLC, toll free at 1-855-793-5068 or by e-mail at shareholder@broadridge.com. |
Q: |
What
happens if the final Subscription Price is less than the Initial Price? |
A: |
If,
on the Expiration Date, the Alternate Price is lower than the Initial Price, any Excess Subscription Amounts will be allocated
towards the purchase of additional shares of common stock. When submitting your subscription, you should assume that the Subscription
Price will equal the Initial Price of $1.05 per share. However, if the Alternate Price is lower than the Initial Price, the
final Subscription Price will be the Alternate Price. For example, if you want to exercise your Subscription Rights to purchase
100 shares of common stock, you will promptly send payment to the subscription agent in the amount of $105. If the final Subscription
Price per share remains at the Initial Price, you will receive 100 shares of common stock. If the Alternate Price was equal
to $0.99 per share, the final Subscription Price will be the Alternate Price of $0.99 per share. In such case, you will receive
106 shares of common stock rather than 100, and, because we will not issue fractional shares of common stock, you will also
receive a refund of $0.06. The excess amount of cash for any fractional shares of common stock will be returned to you as
soon as practicable, in the form in which made. You will not receive interest or a deduction on any payments refunded to you
under the Rights Offering. Detailed instructions to exercise your Subscription Rights, including regarding payment of the
Subscription Price, are also included on your rights certificate. For assistance you may contact the information agent, Broadridge
Corporate Issuer Solutions, LLC, toll free at 1-855-793-5068 or by e-mail at shareholder@broadridge.com. |
Q: |
What
is the Basic Subscription Right? |
A: |
Each
Right gives our stockholders the right to purchase 2.152353 shares of common stock at the Initial Price, which shall be payable
in cash and subject to the limits described below. To the extent that the Alternate Price is lower than the Initial Price,
we will sell additional shares of common stock. We have granted to you, as a stockholder of record as of 4:00 p.m., Eastern
Time on the Record Date, one Subscription Right for every one share of our common stock you owned at that time. For example,
if you owned 100 shares of our common stock as of 4:00 p.m., Eastern Time on the Record Date, you would have received Subscription
Rights to purchase 215 shares of common stock at the Initial Price, subject to certain limitations. You may exercise all or
a portion of your Basic Subscription Rights or you may choose not to exercise any Rights at all. However, if you exercise
fewer than all of your Basic Subscription Rights, you will not be entitled to purchase any additional shares of common stock
pursuant to the Over-Subscription Right. |
Q: |
What
is the Over-Subscription Right? |
A: |
We
do not expect all of our stockholders to exercise all of their Basic Subscription Rights. The Over-Subscription Right provides
stockholders that exercise all of their Basic Subscription Rights the opportunity to purchase shares of common stock that
are not purchased by other stockholders. If you fully exercise your Basic Subscription Right, the Over-Subscription Right
entitles you to subscribe for additional shares of common stock unclaimed by other holders of rights in this Rights Offering
at the same Subscription Price per share. If an insufficient number of shares is available to fully satisfy all proper Over-Subscription
Right requests, the available shares will be distributed proportionately among Subscription Rights holders who properly exercise
their Over-Subscription Right based on the number of shares each Subscription Rights holder timely subscribed and paid for
under the Basic Subscription Right. The proration process will be repeated until all shares of common stock have been allocated
or all properly made Over-Subscription Right exercises have been fulfilled, whichever occurs earlier. |
In
order to properly exercise your Over-Subscription Right, you must deliver the subscription payment for exercise of your Over-Subscription
Right before the expiration of the Rights Offering. Because we will not know the total number of unsubscribed shares of common
stock before the expiration of the Rights Offering, if you wish to maximize the number of shares you purchase pursuant to your
Over-Subscription Right, you will need to deliver payment in an amount equal to the aggregate Subscription Price for the maximum
number of shares of common stock available, assuming that no stockholder other than you has purchased any shares of common stock
pursuant to such stockholder’s Basic Subscription Right and Over-Subscription Right. Any excess subscription payments received
by the subscription agent caused by proration will be returned by the subscription agent to you by mail, without interest or penalty,
as soon as practicable after the Expiration Date of the Rights Offering. The subscription agent will return any excess payments
in the form in which it was made. Any Excess Subscription Amount resulting from the reduction of the Subscription Price from the
Initial Price to the Alternate Price will be allocated towards the purchase of additional shares of common stock (either towards
your Basic Subscription Right, if available, or towards the Over-Subscription Right if you have already exercised your Basic Subscription
Right in full). See “The Rights Offering — Subscription Rights — Over-Subscription Rights” beginning
on page 40.
Q: |
Who
will receive Subscription Rights? |
A: |
Holders
of our common stock will receive one Right for every one share of common stock owned as of 4:00 p.m., Eastern Time on the Record Date. |
Q: |
How
many shares of common stock may I purchase if I exercise my Subscription Rights? |
A: |
Each
Right evidences a right to purchase 2.152353 shares of common stock at the Initial Price, which shall be paid in cash. To
the extent that the Alternate Price is lower than the Initial Price, we will sell additional shares of common stock. You may
exercise any number of your Subscription Rights. You are urged to obtain a current price quote for our common stock before
exercising your Subscription Rights. |
Q: |
Am
I required to subscribe in the Rights Offering? |
A: |
No. |
Q: |
What
happens if I choose not to exercise my Subscription Rights? |
A: |
If
you choose not to exercise your Subscription Rights, you will retain your current number of shares of common stock of the
Company. If other stockholders fully exercise their Subscription Rights or exercise a greater proportion of their Subscription
Rights than you exercise, the percentage of our common stock owned by these other stockholders will increase relative to your
ownership percentage, and your voting and other rights in the Company will likewise be diluted. |
Q: |
Am
I required to exercise all of the Subscription Rights I receive in the Rights Offering? |
A: |
No.
You may exercise any number of your Subscription Rights, or you may choose not to exercise any Subscription Rights. If you
do not exercise any Subscription Rights, the number of shares of our common stock you own will not change; however, you will
own a smaller proportional interest in us than if you had timely exercised all or a portion of your Subscription Rights. If
you choose not to exercise your Subscription Rights or you exercise fewer than all of your Subscription Rights and other stockholders
fully exercise their Subscription Rights or exercise a greater proportion of their Subscription Rights than you exercise,
the percentage of our common stock owned by these other stockholders will increase relative to your ownership percentage,
and your voting and other rights in us will likewise be diluted. In addition, if you do not exercise your Basic Subscription
Right in full, you will not be entitled to participate in the Over-Subscription Right. |
Q: |
If
I am a holder of stock options or warrants, may I participate in the Rights Offering? |
A: |
No.
Holders of outstanding stock options or warrants on the Record Date will not be entitled to participate in the Rights Offering,
except to the extent they hold shares of our common stock on the Record Date. |
Q: |
Will
the equity awards of our employees, officers and directors automatically convert into common stock in connection with the
Rights Offering? |
A: |
No,
equity awards will not automatically convert into common stock. Holders of our equity awards, including outstanding stock
options, will not receive rights in the Rights Offering in connection with such equity awards, but will receive Subscription
Rights in connection with any shares of our common stock held as of the Record Date. |
Q: |
How
soon must I act to exercise my Subscription Rights? |
A: |
If
you received a rights certificate and elect to exercise any or all of your Subscription Rights, the subscription agent must
receive your completed and signed rights certificate and payment (and your payment must clear) prior to the expiration of
the Rights Offering, which is [●], at 4:00 p.m., Eastern Time. If you hold your shares in the name of a custodian bank,
broker, dealer or other nominee, your nominee may establish a deadline prior to 5:00 p.m., Eastern Time, on [●] by which
you must provide it with your instructions to exercise your Subscription Rights and payment for your common stock. Our board
of directors may, in its discretion, extend the Rights Offering one or more times. Our board of directors may cancel or amend
the Rights Offering at any time before its expiration. In the event that the Rights Offering is cancelled, all subscription
payments received will be returned promptly, without interest or penalty. |
Q: |
Does
Summit need to achieve a minimum participation level in order to complete the Rights Offering? |
A: |
No.
We may choose to consummate, amend, extend or terminate the Rights Offering regardless of the number of shares of common stock
actually subscribed for by stockholders. |
Q: |
Can
Summit terminate the Rights Offering? |
A: |
Yes.
Our board of directors may decide to terminate the Rights Offering at any time prior to the expiration of the Rights Offering,
for any reason. If we cancel the Rights Offering, any money received from subscribing stockholders will be refunded as soon
as practicable, without interest or a deduction on any payments refunded to you under the Rights Offering. See “The
Rights Offering — Expiration of the Rights Offering and Extensions, Amendments and Termination” beginning
on page 41. |
Q: |
May
I transfer my Subscription Rights if I do not want to purchase any shares of common stock? |
A: |
No.
Should you choose not to exercise your Subscription Rights, you may not sell, give away or otherwise transfer your Subscription
Rights. However, rights will be transferable as required by operation of law, for example, upon the death of the recipient. |
Q: |
When
will the Rights Offering expire? |
A: |
The
Subscription Rights will expire and will have no value, if not exercised prior thereto, at 5:00 p.m., Eastern Time, on [●],
unless we decide to extend the Expiration Date until some later time or terminate it earlier. See “The Rights Offering
— Expiration of the Rights Offering and Extensions, Amendments and Termination” beginning on page 41. The
subscription agent must actually receive all required documents and payments in cash, as provide herein, before the Expiration
Date. There is no maximum duration for the Rights Offering. |
Q: |
Is
there a guaranteed delivery period? |
A: |
No.
There is no guaranteed delivery period in connection with this Rights Offering, so you must ensure that you properly complete
all required steps prior to 5:00 p.m., Eastern Time, on [●], unless we decide to extend the Expiration Date until some
later time or terminate it earlier. |
Q: |
How
do I exercise my Subscription Rights if I own shares in certificate form? |
A: |
You
may exercise your Subscription Rights by properly completing and executing your rights certificate and delivering it, together
in full with the Subscription Price for each share of common stock you subscribe for, to the subscription agent on or prior
to the Expiration Date. If you use mail, we recommend that you use insured, registered mail, return receipt requested. |
If
you send a payment that is insufficient to purchase the number of shares of common stock you requested, or if the number of shares
of common stock you requested is not specified in the forms, the payment received will be applied to exercise your Subscription
Rights to the fullest extent possible based on the amount of the payment received, subject to the availability of shares of common
stock in the Rights Offering and the elimination of fractional shares. Any excess subscription payments received by the subscription
agent will be returned promptly, without interest, following the expiration of the Rights Offering.
|
Q: |
What
form of payment is required to purchase shares of common stock? |
|
A: |
As
described in the instructions accompanying the rights certificate, you must timely pay the full Subscription Price for the
full number of shares of common stock you wish to acquire under your Subscription Rights at the Initial Price by delivering
to Broadridge Corporate Issuer Solutions, LLC, the subscription agent for this Rights Offering, a certified check, money order,
or wire transfer of funds, or as otherwise acceptable to the Company. |
Please
note that we will not accept payment by means of uncertified personal check, bank draft or cashier’s check.
Q: |
What
should I do if I want to participate in the Rights Offering but my shares are held in the name of my custodian bank, broker,
dealer or other nominee? |
A: |
If
you hold our common stock through a custodian bank, broker, dealer or other nominee, we will ask your custodian bank, broker,
dealer or other nominee to notify you of the Rights Offering. If you wish to exercise your Subscription Rights, you will need
to have your custodian bank, broker, dealer or other nominee act for you. To indicate your decision, you should complete and
return to your custodian bank, broker, dealer or other nominee the form entitled “Beneficial Owner Election Form”
substantially in the form accompanying this prospectus. You should receive this form from your custodian bank, broker, dealer
or other nominee with the other Rights Offering materials. You should contact your custodian bank, broker, dealer or other
nominee if you believe you are entitled to participate in the Rights Offering but you have not received this form. |
Q: |
What
should I do if I want to participate in the Rights Offering, but I am a stockholder with a foreign address or a stockholder
with an Army Post Office or Fleet Post Office address? |
A: |
The
subscription agent will not mail rights certificates to you if you are a registered stockholder whose address is outside the
United States or if you have an Army Post Office or a Fleet Post Office address. To exercise your Subscription Rights, you
must notify the subscription agent prior to 11:00 a.m., Eastern Time, at least three (3) business days prior to the Expiration
Date, and establish to the satisfaction of the subscription agent that it is permitted to exercise your Subscription Rights
under applicable law. If you do not follow these procedures by such time, your Subscription Rights will expire and will have
no value. If you hold your shares in the name of a custodian bank, broker, dealer or other nominee, you should follow the
instructions you receive from it, as described above. |
Q: |
Will
I be charged a sales commission or a fee if I exercise my Subscription Rights? |
A: |
We
will not charge a brokerage commission or a fee to Subscription Rights holders for exercising their Subscription Rights. However,
if you exercise your Subscription Rights through a custodian bank, broker, dealer or nominee, you will be responsible for
any fees charged by your custodian bank, broker, dealer or nominee. |
Q: |
Are
there any conditions to my right to exercise my Subscription Rights? |
A: |
Yes.
We may terminate the Rights Offering, in whole or in part, if at any time before completion of the Rights Offering there is
any judgment, order, decree, injunction, statute, law or regulation entered, enacted, amended or held to be applicable to
the Rights Offering that in the sole judgment of our board of directors would or might make the Rights Offering or its completion,
whether in whole or in part, illegal or otherwise restrict or prohibit completion of the Rights Offering. See “The
Rights Offering — Conditions to the Rights Offering” beginning on page 43. |
Q: |
Has
the board of directors made a recommendation regarding the Rights Offering? |
A: |
Neither
the Company, nor our board of directors is making any recommendation as to whether or
not you should exercise your Subscription Rights. You are urged to make your decision
based on your own assessment of the Rights Offering, after considering all of the information
herein, including the “Risk Factors” beginning on page 23 of this
prospectus, and of your best interests.
|
Q: |
Have
any directors, officers, and/or stockholders agreed to exercise their rights? |
A: |
All
holders of our common stock as of the Record Date for the Rights Offering will receive, at no charge, the non-transferable
Subscription Rights to purchase shares of common stock as described in this prospectus. To the extent that our directors and
officers held shares of our common stock (including shares of restricted common stock) as of the Record Date, they will receive
the Subscription Rights and, while they are under no obligation to do so, will be entitled to participate in the Rights Offering. |
|
|
Robert
W. Duggan, our Executive Chairman, Chief Executive Officer, and the beneficial owner of approximately 78.1% of our outstanding
common stock prior to this Rights Offering, and Dr. Mahkam Zanganeh, our co-Chief Executive Officer, President, a member of our
Board of Directors, and the beneficial owner of approximately 6.0% of our issued and outstanding common stock prior to this Rights
Offering, have each indicated that they intend to participate in the Rights Offering and subscribe for at least the full amount
of their Basic Subscription Rights, but have not made any formal binding commitment to participate.
Q: |
May
stockholders in all states participate in the Rights Offering? |
A: |
Although
we intend to distribute the rights to all stockholders, we reserve the right in some states to require stockholders, if they
wish to participate, to state and agree upon exercise of their respective rights that they are acquiring the securities for
investment purposes only, and that they have no present intention to resell or transfer any securities acquired. Our securities
are not being offered in any jurisdiction where the offer is not permitted under applicable local laws. |
Q: |
Are
there risks in exercising my Subscription Rights? |
A: |
The
exercise of your Subscription Rights involves significant risks. Exercising your Subscription Rights means buying our common
stock, and should be considered as carefully as you would consider any other equity investment. Among other things, you should
carefully consider the risks described under the heading “Risk Factors,” beginning on page 23. |
Q: |
How
many shares of our common stock will be outstanding after the Rights Offering? |
A: |
The
number of shares of our common stock that will be outstanding after the Rights Offering will depend on the number of shares
of common stock that are purchased in the Rights Offering. Assuming no additional shares of common stock are issued by us
prior to consummation of the Rights Offering and assuming all offered shares of common stock are sold in the Rights Offering
at the Initial Price, we will issue approximately 476,190,476 shares of common stock. In that case, we will have approximately
697,432,201 shares of common stock outstanding after the Rights Offering. This would represent an increase of approximately
215% in the number of outstanding shares of common stock. To the extent that the Alternate Price is lower than the Initial
Price, we will sell additional shares of common stock and the number of shares of common stock outstanding after the Rights
Offering will accordingly be higher. However, we will not issue shares in excess of the total amount authorized by our Board
of Directors. |
The
issuance of shares of our common stock in the Rights Offering will dilute, and thereby reduce, your proportionate ownership in
our shares of common stock, unless you fully exercise your Basic Subscription Rights. In addition, the issuance of our common
stock at a Subscription Price that is less than the market price as of the Record Date for the Rights Offering will likely reduce
the price per share of our common stock held by you prior to the Rights Offering.
Q: |
What
will be the proceeds of the Rights Offering? |
A: |
If
all rights are exercised, we will receive gross proceeds of approximately $500 million before expenses, as provided herein.
We are offering shares of common stock in the Rights Offering with no minimum purchase requirement. As a result, there is
no assurance we will be able to sell all or any of the shares of common stock being offered, and it is not likely that all
of our stockholders will participate in the Rights Offering. |
Q: |
After
I exercise my Subscription Rights, can I change my mind and cancel my purchase? |
A: |
No.
Once you exercise and send in your Subscription Rights certificate and subscription payment, as provided herein, you cannot
revoke the exercise of your Subscription Rights, even if you later learn information about the Company that you consider to
be unfavorable. You should not exercise your Subscription Rights unless you are certain that you wish to purchase shares of
common stock at the Initial Price. See “The Rights Offering — No Revocation or Change” beginning
on page 46. |
Q: |
What
are the material U.S. Federal income tax consequences of exercising my Subscription Rights? |
A: |
Although
the authorities governing transactions such as this Rights Offering are complex and unclear in certain respects, we believe
and intend to take the position that the distribution of Subscription Rights to a holder with respect to such holder’s
shares of common stock generally should be treated, for U.S. federal income tax purposes, as a non-taxable distribution.
For a more detailed discussion, see “Material U.S. Federal Income Tax Consequences” beginning on page
48. You should consult your tax advisor as to the particular consequences to you of the Rights Offering. |
Q: |
If
the Rights Offering is not completed, for any reason, will my subscription payment be refunded to me? |
A: |
Yes.
The subscription agent will hold all funds it receives in a segregated bank account until the Rights Offering is completed.
If the Rights Offering is not completed, for any reason, any money received from subscribing stockholders will be refunded
in the form which paid as soon as practicable, without interest or deduction. If your shares are held in the name of a custodian
bank, broker, dealer or other nominee, it may take longer for you to receive the refund of your subscription payment than
if you were a record holder of your shares because the subscription agent will return payments through the record holder of
your shares. |
Q: |
Will
I receive interest on any funds I deposit with the subscription agent? |
A: |
No.
You will not be entitled to any interest on any funds that are deposited with the subscription agent pending completion or
cancellation of the Rights Offering. If the Rights Offering is cancelled for any reason, the subscription agent will return
this money to subscribers, without interest or penalty, as soon as practicable. |
Q: |
If
I exercise my Subscription Rights, when will I receive my shares of common stock that I purchased in the Rights Offering? |
A: |
We
will issue the shares of common stock purchased in the Rights Offering to you in book-entry, or uncertificated, form of our
common stock purchased in the Rights Offering as soon as practicable after the expiration of the Rights Offering and after
all pro rata allocations and adjustments have been completed. We will not be able to calculate the number of shares to be
issued to each exercising holder until after the Expiration Date of the Rights Offering. |
Q: |
When
can I sell the shares of common stock I receive in the Rights Offering? |
A: |
If
you exercise your Subscription Rights and receive common stock, you will be able to resell the shares of common stock once
your account has been credited with those shares, provided you are not otherwise restricted from selling the shares (for example,
because you are an insider or affiliate of the Company or because you possess material nonpublic information about the Company).
Although we will endeavor to issue the shares as soon as practicable after completion of the Rights Offering, there may be
a delay between the Expiration Date of the Rights Offering and the time that the shares are issued due to factors such as
the time required to complete all necessary calculations. In addition, following the exercise of your Subscription Rights,
you may not be able to sell the shares purchased in the Rights Offering at a price equal to or greater than the Subscription
Price. |
Q: |
To
whom should I send my forms and payment? |
A: |
If
your shares are held in the name of a custodian bank, broker, dealer or other nominee, the nominee will notify you of the
Rights Offering and provide you with the Rights Offering materials, including a form entitled “Beneficial Owners Election
Form.” You should send the Beneficial Owner Election Form and payment, as provided therein, to the nominee, at the deadline
that your nominee sets which may be earlier than the expiration of the Rights Offering. You should contact your custodian
bank, broker, dealer or other nominee if you believe you are entitled to participate in the Rights Offering but you have not
received this form. |
|
|
If
your shares are held in your name such that you are the record holder, then you should send your subscription documents, rights
certificate and subscription payment, as provided herein, by first class mail or courier service to Broadridge Corporate Issuer
Solutions, LLC, the subscription agent. The address for delivery to the subscription agent is as follows:
By
Mail:
Broadridge
Corporate Issuer Solutions, LLC
Attn:
BCIS Re-Organization Dept.
P.O.
Box 1317
Brentwood,
NY 11717-0718
|
By
Overnight Delivery:
Broadridge
Corporate Issuer Solutions, LLC
Attn:
BCIS IWS
51
Mercedes Way
Edgewood,
NY 11717 |
Your
delivery to a different address or other than by the methods set forth above will not constitute valid delivery. You, or, if applicable,
your nominee, are solely responsible for ensuring the subscription agent receives your subscription documents, rights certificate,
and subscription payment. You should allow sufficient time for delivery of your subscription materials to the subscription agent
and clearance of payment before the expiration of the Rights Offering period.
Q: |
Will
this Rights Offering result in the Company “going private” for purposes of Rule 13e-3 of the Exchange Act? |
A: |
No.
The Rights Offering is not a transaction or series of transactions which has either a reasonable likelihood or a purpose or
producing a “going private effect” as specified in Rule 13e-3 of the Exchange Act. Given the structure of the
Rights Offering, as described in this prospectus, the Company will continue to be registered pursuant to Section 12 of the
Exchange Act and intends to remain listed on the Nasdaq Global Market following completion of the Rights Offering. |
Q: |
What
if I have other questions? |
A: |
If
you have other questions about the Rights Offering, please contact our information agent, Broadridge Corporate Issuer Solutions,
LLC, toll free at 1-855-793-5068, by e-mail at shareholder@broadridge.com, or by mail at: |
|
|
Broadridge
Corporate Issuer Solutions, LLC
Attn: BCIS Re-Organization Dept.
P.O. Box 1317
Brentwood, NY 11717-0718
PROSPECTUS
SUMMARY
This
summary highlights certain information about us, this Rights Offering and selected information contained in the prospectus. This
summary is not complete and does not contain all of the information that you should consider before deciding whether to invest
in our common stock. For a more complete understanding of the Company and this Rights Offering, we encourage you to read and consider
the more detailed information included or incorporated by reference in this prospectus, including risk factors, see “Risk
Factors” beginning on page 23, and our most recent consolidated financial statements and related notes. As described below,
on December 5, 2022, we entered into the License Agreement (as defined below), pursuant to which we will partner with Akeso (as
defined below) to in-license its breakthrough bispecific antibody, ivonescimab, known as AK112 in China and Australia, and also
as SMT112 in the United States, Canada, Europe, and Japan. The License Agreement and transactions contemplated thereby closed
on January 17, 2023.
Overview
We
are a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver-
and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve
serious unmet medical needs. Our pipeline of product candidates is designed with the goal to become the patient-friendly, new-era
standard-of-care medicines.
On
September 28, 2022, we determined that we would seek partners or a divestiture of ridinilazole, our lead product candidate for
treating patients suffering from Clostridioides difficile infection, also known as C. difficile infection, or CDI,
as the path forward for the clinical development of the asset. As a result of this determination, we discontinued our only active
study for ridinilazole, a pediatric clinical trial evaluating ridinilazole for treating adolescent patients with CDI. We are currently
involved in activities related to closeout of ridinilazole clinical trials.
Our
second product candidate, SMT-738, is being developed for combating multidrug resistant infections, specifically carbapenem-resistant
Enterobacteriaceae (“CRE”) infections. SMT-738 is the first of a novel class of precision antibiotics that has entered
into preclinical development. SMT-738 is currently undergoing IND-enabling activities. We have been and will continue to pursue
partnership discussions to continue the development of SMT-738.
We
have two additional discovery-phase targets in our pipeline with undisclosed targets in the therapeutic area of oncology.
On
December 5, 2022, we entered into a Collaboration and License Agreement (the “License Agreement”) with Akeso, Inc.
and its affiliates (“Akeso”) pursuant to which we are partnering with Akeso to in-license its breakthrough bispecific
antibody, ivonescimab. Ivonescimab, known as AK112 in China and Australia, and also as SMT112 in the United States, Canada, Europe,
and Japan, is a novel, potential first-in-class bispecific antibody intending to combine the power of immunotherapy via a blockade
of PD-1 with the anti-angiogenesis benefits of an anti-VEGF into a single molecule. Ivonescimab was engineered to bring two well
established oncology targeted mechanisms together. Through the License Agreement, we obtained the rights to develop and commercialize
SMT112 in the United States, Canada, Europe, and Japan. The License Agreement and transactions contemplated thereby closed on
January 17, 2023.
The
entry into the License Agreement and potential partnership or divestiture of ridinilazole represents a material shift in the Company’s
strategy. All prior development and marketing activities relating to ridinilazole are being terminated and our future operations
will be heavily dependent on the License Agreement and other future activities as the Company determines. The success of this
transaction will depend, in part, on the clinical success of ivonescimab as well as the success of our collaboration with Akeso.
This transaction may not result in the realization of the full benefit of any anticipated growth opportunities or these benefits
may not be realized within the expected time frames. We will also require significant additional financing to fund the clinical
development plan and certain payments contemplated by the License Agreement that could result in an increase in the number of
our outstanding shares or the aggregate amount of our debt. If we are unable to raise capital to fund these additional payments,
it may cause a material adverse effect on our business.
We
have devoted substantially all of our efforts to research and development, including clinical trials. We have not completed the
development of any drugs. We expect to continue to incur significant expenses and increasing operating losses for at least the
next few years. The net losses we incur may fluctuate significantly from quarter to quarter and year to year, due to the nature
and timing of our research and development activities. We expect that our research and development and general and administrative
expenses will continue to be significant in connection with our ongoing research and development efforts.
Collaboration
and License Agreement
Our
License Agreement with Akeso, as referred to above, calls for Summit to receive the rights to develop and commercialize ivonescimab
in the United States, Canada, Europe, and Japan (the “Licensed Territory”). Akeso will retain development and
commercialization rights for the rest of the regions including China. In exchange for these rights, Summit will make an upfront
payment of $500 million, $300 million of which is payable within the later of 15 days after execution of the License Agreement or
upon the earliest date on which the parties have actual knowledge that all applicable waiting periods under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976 and any comparable extension periods with respect to the transactions contemplated by the License
Agreement have expired or been terminated (the “Antitrust Clearance Date”) and $200 million of which is payable within
the later of (i) 90 days after execution of the License Agreement or (ii) the Antitrust Clearance Date. In connection with the first payment, up to 16 million shares
of Company common stock may be issued in lieu of cash at Akeso’s election (the “Share Transfer”), with the value
of such shares based on the ten (10) day volume-weighted average price for the five-trading day period prior to and the five-trading
day period after the execution of the License Agreement. The total of the upfront payment and potential milestone payments is $5.0
billion, as Akeso will be eligible to receive regulatory milestones of up to $1.05 billion and commercial milestones of up to $3.45
billion. In addition, Akeso will be eligible to receive low double-digit royalties on net sales. Following the Antitrust Clearance
Date, on January 17, 2023, the License Agreement closed and, as initial upfront payment, Akeso was issued 10 million shares of
Company common stock pursuant to the Share Transfer and was paid $274.9 million dollars in cash. The $200 million remaining amount
of the $500 million upfront payment is payable on March 5, 2023. In connection with the License Agreement, the Company has also
agreed to enter into a Supply Agreement with Akeso, pursuant to which Summit agreed to purchase a certain portion of drug substance
for clinical and commercial supply (the “Supply Agreement”).
Pursuant
to the terms of the License Agreement, Summit will have final decision-making authority with respect to commercial strategy, pricing
and reimbursement and other commercialization matters in the Licensed Territory. Summit is not assuming any liabilities (including
contingent liabilities), acquiring any physical assets or trade names, or hiring or acquiring any employees from Akeso in connection
with the License Agreement. Akeso has incurred research and development expenses relating to ivonescimab, including expenses for
pre-clinical studies, as well as safety and efficacy clinical trials in non-licensed territories.
Our
Strategy
Our
goal is to become a fully integrated biopharmaceutical company focused on the discovery, development, and commercialization of
our pipeline product portfolio in the therapeutic area of oncology and/or new era products that work in harmony with the human
gut microbiome, including innovative therapeutics for the treatment of certain cancers and infectious diseases.
Product
Pipeline
![](https://content.edgar-online.com/edgar_conv_img/2023/01/23/0001387131-23-000472_smmt-007.jpg)
Ivonescimab
Ivonescimab
is believed to be the PD-1 / VEGF bispecific antibody that is most advanced in the clinic. Ivonescimab has received Breakthrough
Therapy Designation status in China from the NMPA for three indications: combination therapy with chemotherapy for NSCLC patients
who have failed a previous EGFR-TKI, combination therapy with chemotherapy for NSCLC patients who have failed to respond to a
prior PD-(L)1 therapy, and monotherapy as first-line treatment for locally advanced or metastatic NSCLC patients with positive
PD-L1 expression. Ivonescimab is currently being developed in China and Australia in multiple solid tumors, including a Phase
III clinical trial in patients with NSCLC that is positive for an epidermal growth factor receptor (EGFR) mutation whose disease
has progressed after treatment with an EGFR tyrosine-kinase inhibitor (TKI). As
presented at ASCO 2022, ivonescimab treatment was associated with an overall response rate (ORR) in a Phase II study in patients
with non-small cell lung cancer (NSCLC) who have failed EGFR-TKI’s of 68.4% and a median Progression-Free Survival (mPFS)
time period of 8.2 months when combined with combination chemotherapy (pemetrexed and carboplatin) as compared to historical mPFS
of 4.3 months in patients treated with combination chemotherapy (pemetrexed and platinum-based chemotherapy) alone, the current
standard of care. In a separate cohort, ivonescimab combined with docetaxel in patients who have failed PD-(L)1 and chemotherapies
demonstrated a mPFS of 6.6 months as compared to a historical mPFS of 4.5 months with docetaxel alone, a current standard of care
regimen for these patients. The study, which similarly had patients receiving ivonescimab plus chemotherapy as their first line
therapy for metastatic disease, was considered to have demonstrated a tolerable safety profile and a low discontinuation rate
for adverse events.
Summit
has clinical development and commercialization rights for SMT112 in its Licensed Territory (United States, Canada, Europe, and
Japan). Summit plans to design and conduct the clinical trial activities for SMT112 in its Licensed Territory, to support and
submit relevant regulatory filings. Summit is initiating development activities for ivonescimab and will do so first in NSCLC
indications. Summit plans to start treating patients in clinical studies by the second quarter of 2023.
Discuva
Platform
In
December 2017, we expanded our activities in the field of infectious diseases with the acquisition of Discuva Limited, a privately
held United Kingdom-based company. Through this acquisition, we obtained a bacterial genetics platform and a suite of software-based
technologies (collectively termed our “Discuva Platform”), which facilitate the discovery and development of new mechanism
antibiotics. Our Discuva Platform can be used to identify new bacterial targets for drug discovery, understand the mechanism of
action of small molecules targeting varying types of bacteria and select the most optimal preclinical candidates, including those
with the least propensity to develop bacterial resistance. On January 20, 2023, we announced that given the License Agreement and the Company’s shift in focus to oncology, we will cease further
investment in theDiscuva platform and evaluate further options for the use of the Discuva Platform. Based on the evaluation of further
options for the use of the Discuva Platform, we willassess the carrying value of the acquired Discuva Platform intangible asset.
Enterobacteriaceae
Program
We
continue to advance our highly innovative program targeting infections caused by Enterobacteriaceae. We have used our Discuva
Platform to identify our DDS-04 series, a novel chemotype active against a clinically unexploited bacterial target that has the
potential to treat Enterobacteriaceae infections. Enterobacteriaceae are a family of bacteria responsible for serious infections
across a number of conditions including bloodstream infections, urinary tract infections (“UTI”) and hospital-acquired
pneumonias. Multi-drug resistant (“MDR”) Enterobacteriaceae are resistant to treatment by most or occasionally all
existing antibiotics. The most difficult to treat among them are the Extended Spectrum Beta-Lactamase (“ESBL”)-producing
and the Carbapenem-resistant CRE. According to the Center for Disease Control and Prevention (“CDC”), ESBL-producing
and CRE Enterobacteriaceae have collectively caused an estimated 197,400 infections and 9,100 deaths in hospitalized patients
in the United States in 2019. Our DDS-04 series continues to build on highly promising preclinical in vivo efficacy data
with an immediate focus on a new antibiotic agent for the treatment of complicated urinary tract infections, pneumonia and the
associated bacteremia.
Our
lead preclinical candidate for the Enterobacteriaceae program from the DDS-04 series is SMT026738 (formerly “DIS-0104145”
and referred to as “SMT-738”). SMT-738 is a novel small molecule inhibitor of the essential bacterial lipoprotein
transport system (LolCDE) in Gram-negative bacteria, which displays a narrow spectrum of activity towards Enterobacteriaceae.
SMT-738 has demonstrated potent in vitro activity against global MDR isolates of E. coli and K. pneumoniae, including
the clinically challenging NDM-carrying CRE isolates where many currently available treatment options have succumbed to clinical
resistance including colistin, an antibiotic of last resort. Most importantly, SMT-738 has also shown robust in vivo efficacy
in relevant murine models of UTI, pneumonia and sepsis. A preliminary rodent toxicity study has been concluded and the data supports
the continued clinical development of SMT-738. SMT-738 has the potential to become a first in class antibiotic to treat life-threatening
infections. We retain worldwide clinical development and commercial rights to SMT-738 and plan to continue to perform IND-enabling
activities. We have been and will continue to pursue partnership discussions to continue the development of SMT-738.
Other
Material Agreements
On
December 6, 2022, we entered into a Note Purchase Agreement (the “Note Purchase Agreement”) and promissory notes with
Robert W. Duggan, the Company’s Chief Executive Officer, Chairman of the Board, and beneficial owner of approximately 78.1%
of the Company’s common stock and Dr. Mahkam Zanganeh, the Company’s co-Chief Executive Officer, President, member of
the Board and beneficial owner of approximately 6.0% of the Company’s common stock. Pursuant to the Note Purchase Agreement,
the Company agreed to sell to Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $520 million.
Pursuant
to the Note Purchase Agreement, the Company has issued to Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the amount
of $400 million and $20 million, respectively (the “February Notes”), which will mature and become due on February
15, 2023 (the “February Maturity Date”) and an unsecured promissory note to Mr. Duggan in the amount of $100 million
(the “September Note” and together with the February Notes, the “Notes”), which will mature and become
due on September 15, 2023 (the “September Maturity Date” and together with the February Maturity Date, the “Maturity
Dates”). The Maturity Dates may be extended one or more times at the Company’s election, but in no event to a date
later than September 6, 2024. The Notes accrue interest at an initial rate of 7.5%. All interest on the Notes shall be paid on
the date of signing for the period through the February Maturity Date. Such prepaid interest shall be paid in a number of shares
of the Company’s common stock, par value $0.01 equal to the dollar amount of such prepaid interest, divided by $0.7913 (the
consolidated closing bid price immediately preceding the time the Company entered into the Note Purchase Agreement, plus $0.01),
which is 9,720,291 shares. If the Company exercises its right to extend the term of the February Notes for all periods following
the February Maturity Date and, with respect to the September Note following the February Maturity Date, interest shall accrue
on the outstanding balance of such extended Notes at the US prime interest rate plus 50 basis points, as adjusted monthly, for
three months immediately following the Maturity Date, and thereafter at the US prime rate plus 300 basis points, as adjusted monthly,
in each case payable in cash quarterly in arrears. In addition, if the Company shall consummate a public offering, then upon the
later to occur of (i) five business days after the Company receives the net cash proceeds therefrom or (ii) May 15, 2023, the
February Notes shall be prepaid by an amount equal to the lesser of (a) 100% of the amount of the net proceeds of such offering
and (b) the outstanding principal amount on such Notes. In January 2023, the Company provided notice to Mr. Duggan that it has
elected to extend the Maturity Dates of the $400 million February Note and the September Note to September 6, 2024. The Company and Mr. Duggan have rectified the $400 million February Note and the September Note in order to correctly reflect the parties’
intent in such notes that the Company may only prepay (i) the $400 Million February Note following the completion of the Rights Offering,
or a similar capital raise, in an amount equal to the lesser of (x) the net proceeds of the Rights Offering or such capital raise or (y)
the full amount outstanding of the such note, and (ii) the September Note following the completion of a capital raising transaction subsequent
to the Rights Offering in an amount equal to the lesser of (i) the net proceeds of such capital raise or (ii) the full amount outstanding
of the September Note.
The
Company intends to repay the February Notes within five business days following the consummation of this Rights Offering in an
amount equal to the lesser of (a) 100% of the amount of the net proceeds of the Rights Offering and (b) the outstanding principal
amount on such Notes. The Notes were issued to Mr. Duggan and Dr. Zanganeh, as applicable, in a private placement in reliance
on Regulation D promulgated under the Securities Act of 1933, as amended. The Notes have not been registered under the Securities
and Exchange Act of 1933, as amended, and may not be offered or sold absent registration or an applicable exemption from registration
requirements.
Liquidity
As
of the date of this filing, the Company has received $520 million from the Note Purchase Agreement as discussed above. On January
17, 2023, Akeso was issued 10 million shares of Company common stock pursuant to the Share Transfer and was paid $274.9 million
dollars in cash. The Company expects to use the proceeds of the Note Purchase Agreement to support (i) payment of the upfront
obligation totaling $500 million associated with the License Agreement as described above (which includes the payment of $274.9
million in cash referenced in the preceding sentence); (ii) activities to support clinical development and regulatory approval
for SMT112; (iii) its pursuit of business development opportunities to expand or enhance our pipeline of drug candidates; and
(iv) general corporate purposes. In January 2023, the Company provided notice to Mr. Duggan that it has elected to extend the
Maturity Dates of the $400 million February Note and the September Note to September 6, 2024.
The
purpose of this Rights Offering is to raise equity capital in a cost-effective manner that provides all of our existing stockholders
the opportunity to participate. The net proceeds will be used for one or more of the following purposes: (i) the repayment of
certain unsecured promissory notes totaling $420 million issued pursuant to the Note Purchase
Agreement and (ii) general corporate purposes, which includes funding the Company’s activities
to support clinical development and regulatory approval for SMT112 and pursue business development opportunities to expand or
enhance our pipeline of drug candidates.
We
believe that our existing cash, cash equivalents and U.K. research and development tax credits, together with the net proceeds
from this Rights Offering after the repayment of certain unsecured promissory notes totaling $420 million issued pursuant to the
Note Purchase Agreement, will be sufficient to fund our operations and initially
planned clinical trials for ivonescimab into the second half of 2024. If the Company is
unable to successfully complete this Rights Offering, or if the net proceeds are significantly less than expected, the
Company would seek other funding alternatives. However, if additional funding is not available, or is not available on terms acceptable
to the Company, the Company will focus its available capital on certain initially planned clinical trials for ivonescimab. This
would allow the Company to be able to operate into the third quarter of 2024. These actions could adversely affect the Company’s
business prospects.
The
Company expects to continue generating operating losses for the foreseeable future. Until the Company can generate substantial
revenue and achieve profitability, the Company will need to raise additional capital to fund its ongoing operations and capital
needs. The Company continues to evaluate options to further finance its operating cash needs for its product candidates through
a combination of some, or all, of the following: equity and debt offerings, collaborations, strategic alliances, grants and clinical
trial support from government entities, philanthropic, non-government and not-for-profit organizations and
patient advocacy groups, and marketing, distribution or licensing arrangements. While
the Company believes that funds would be available in this manner before 2024, there is
no assurance, however, that additional financing will be available when needed or that management of the Company will be able
to obtain financing on terms acceptable to the Company. If the Company is unable to obtain funding when required in the
future, the Company could be required to delay, reduce, or eliminate research and development programs, product portfolio expansion,
or future commercialization efforts, which could adversely affect its business prospects.
Corporate
Information
Summit
Therapeutics Inc. was incorporated in Delaware on July 17, 2020. Our principal executive office is located at 2882 Sand Hill Road,
Suite 106, Menlo Park, California and our phone number is (617) 514-7149. Our website is https://www.smmttx.com.
Information contained on or accessible through our website is not incorporated by reference into this prospectus and should not
be considered a part of this prospectus.
Recent
Developments
In
addition to the recent developments included in this Prospectus Summary, on January 6, 2023 the Company held a Special Meeting
of Stockholders in which the stockholders approved: (i) an amendment to our restated certificate of incorporation to increase
the number of authorized shares of our common stock by 650,000,000 (from 350,000,000 to 1,000,000,000); and (ii) an amendment
to our restated certificate of incorporation to effect a reverse stock split of all of the outstanding shares of our common stock
at a ratio in the range of 1-for-5 to 1-to-10, such that every holder of common stock of the Company shall receive ten to twenty
shares of common stock for every 100 shares of common stock held. On January 19, 2023, the Board approved, and the Company subsequently
filed, an amendment to the amended and restated certificate of incorporation to increase the Company’s capitalization as
described in clause (i). The Board reserves the right to adopt the proposal described in clause (ii) at any time prior to January
6, 2024 but has no intention to effect the reverse stock split prior to the closing of the Rights Offering and issuance of shares
thereunder. For a more detailed discussion, see “Risk Factors” on page 23.
RISK
FACTORS
Investing
in our common stock involves risks. Please carefully consider the risk factors described in our periodic reports filed with the
SEC, including those set forth under the caption “Item 1A. Risk Factors” in our annual report
on Form 10-K for the fiscal year ended December 31, 2021 and quarterly
reports on Form 10-Q filed thereafter, which are incorporated by reference in this prospectus and in any other documents we may
file in the future and that will be incorporated by reference into this prospectus. Before making an investment decision, you
should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus.
You should be able to bear a complete loss of your investment.
Risks
Related to the License Agreement and the Development and Commercialization of Ivonescimab
The
License Agreement and the transactions contemplated thereby represent a material shift in the Company’s strategic focus,
may not achieve intended results and could increase the number of our outstanding shares or amount of outstanding debt.
As
the Company previously announced, on September
28, 2022, we determined that we would seek partners or a divestiture of ridinilazole, our lead product candidate for treating
patients suffering from CDI, as the path forward for the clinical development of the asset. As a result of this determination,
we discontinued our only active study for ridinilazole, a pediatric clinical trial evaluating ridinilazole for treating adolescent
patients with CDI. We are currently involved in activities related to closeout of ridinilazole clinical trials.
On
December 5, 2022 we entered into the License Agreement with Akeso pursuant
to which Akeso granted the Company an in-license to its breakthrough bispecific antibody, ivonescimab, in the Licensed Territory.
The entry into the License Agreement and potential partnership or divestiture of ridinilazole represents a material shift in the
Company’s strategy. All prior development and marketing activities relating to ridinilazole are being terminated and our
future operations will be heavily dependent on the License Agreement and other future activities as the Company determines.
Given the License Agreement and shift in focus to oncology, the Company decided
it will cease further investment in the Discuva platform and evaluate further options for the use of the Discuva Platform. Based
on the evaluation of further options for the use of the Discuva Platform, the Company will assess the carrying value of the acquired
Discuva Platform intangible asset.
The
success of this transaction will depend, in part, on the clinical success of ivonescimab as well as the success of our collaboration
with Akeso. This transaction may not result in the realization of the full benefit of any anticipated growth opportunities or
these benefits may not be realized within the expected time frames. Our Company has no prior history of a successful product candidate
and, as discussed above, we determined that we would seek partners or a divestiture for our prior lead product candidate, ridinilazole,
on September 28, 2022, and will pursue partnership discussions to continue the development of SMT-738. We will also require significant
additional financing to fund the clinical development plan and certain payments contemplated by the License Agreement that could
result in an increase in the number of our outstanding shares or the aggregate amount of our debt. If we are unable to raise capital
to fund these additional payments, it may cause a material adverse effect on our business.
We
will depend heavily on the success of ivonescimab. If we are unable to commercialize ivonescimab, or experience significant delays
in doing so, our business will be materially harmed.
We
plan to invest a significant portion of our efforts and financial resources in the development of ivonescimab, which is still
in clinical development. Our ability to generate product revenues, which may not occur for several years, if ever, will depend
heavily on the successful development and commercialization of ivonescimab. The success of this product candidate will depend
on a number of factors, including the following:
| ● | Ability
to use data of patients from Akeso’s clinical trials in China in seeking regulatory
approval; |
| ● | successful
completion of clinical development; |
| ● | receipt
of marketing approvals from applicable regulatory authorities; |
| ● | establishing
supply chain and commercial manufacturing arrangements with third-party manufacturers; |
| ● | obtaining
and maintaining patent and trade secret protection and regulatory exclusivity; |
| ● | protecting
our rights in our intellectual property portfolio; |
| ● | establishing
sales, marketing and distribution capabilities; |
| ● | launching
commercial sales of ivonescimab if and when approved, whether alone or in collaboration
with others; |
| ● | acceptance
of ivonescimab, if and when approved, by patients, the medical community and third-party
payors; |
| ● | obtaining
adequate pricing and a reimbursement profile; |
| ● | ensuring
no disruption in supply or lack of sufficient quantities of ivonescimab; |
| ● | effectively
competing with other therapies; and |
| ● | maintaining
a continued acceptable safety profile of ivonescimab, following approval. |
If
we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability
to successfully commercialize ivonescimab,
which would materially harm our business.
We
depend on our relationship with, and the intellectual property licensed from, Akeso, and termination of the License Agreement
or any of the licenses under the License Agreement could have a material adverse effect on our business.
We
depend on the know-how and other intellectual property licensed from Akeso through the License Agreement for the development and,
if approved, commercialization of product candidates with the use of Akeso’s bispecific antibody, ivonescimab. If the License
Agreement is terminated, or found to be unenforceable, it could result in the loss of significant rights and could harm our ability
to commercialize ivonescimab.
The
License Agreement imposes certain obligations on us, including obligations to use diligent efforts to meet development thresholds,
funding requirements, payment obligations, patent prosecution and commercialization. Accordingly, disputes may arise between us
and Akeso regarding these obligations and various contract terms, as they relate to the intellectual property subject to the License
Agreement or other issues with intellectual property, including those relating to:
| ● | the
scope of rights, if any, granted under the License Agreement and other interpretation-related
issues; |
| ● | whether
and to what extent our technology and processes infringe on intellectual property rights
of Akeso or other third parties that are not subject to the License Agreement; |
| ● | whether
Akeso had the right to grant the licenses under the License Agreement; |
| ● | whether
third parties are entitled to compensation or equitable relief, such as an injunction,
for our use of intellectual property without their authorization; |
| ● | our
right to sublicense patent and other rights to third parties under collaborative development
relationships; |
| ● | whether
we are complying with our obligations with respect to the use of the licensed technology
in relation to our development and commercialization of product candidates; |
| ● | ownership
of specific intellectual property; |
| ● | our
involvement in and ability to align on the prosecution and enforcement of the licensed
patents and patent applications and Akeso’s overall patent prosecution, intellectual
property protection and enforcement strategies; and |
| ● | the
impact on payments and costs associated with commercialization if there is blocking intellectual
property in or costs associated with prosecution, maintenance and enforcement under the
License Agreement. |
The
resolution of any such disputes, disagreements, or issues that may arise could narrow what we believe to be the scope of our rights
to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under
the relevant agreement.
Our
primary product candidate, ivonescimab, is subject to a license from Akeso, which is revocable in certain circumstances, including
in the event we do not achieve certain payment deadlines. Without the license, we will not be able to continue to develop ivonescimab.
The
License Agreement may be terminated by Akeso in the event of a material breach by us or if we default in the performance of any
of our material obligations under the License Agreement, and such default continues for 90 days, or with respect to any breach
of any undisputed payment obligations, for 60 days, or with respect to any breach of a supply requirement, for 30 days after written
notice thereof. Akeso may also terminate the agreement upon written notice upon the Company’s bankruptcy.
We
may not continue to be able to make the various payment obligations under the License Agreement, including certain significant
payments due upon satisfaction of pre-commercialization milestones. If the License Agreement were to be terminated by Akeso for
any reason, we would lose our most significant asset and primary product candidate, and would likely not be able to develop ivonescimab,
which would have a material adverse effect on our operations.
We
will be reliant on Akeso for knowledge transfer relating to manufacturing of our product candidate. The loss of any of the knowledge
transferred relating to ivonescimab from Akeso may cause us to incur additional transition costs or result in delays in the manufacturing
and delivery of our product candidate.
We
have entered into the License Agreement and the Supply Agreement with Akeso for information and drug substance that we will rely
on to be used in our product candidate, and the termination or Akeso’s breach of these agreements could have a material
adverse effect on our business.
If
we lost our relationship with Akeso we could experience an increase in our costs, result in delays in the manufacturing and delivery
of our product candidate or cause us to carry excess or obsolete inventory. Additionally, poor quality in any of the drug substances
could result in lost sales or lost sales opportunities. Further, failure of Akeso to adequately transfer knowledge to the Company
to continue to produce ivonescimab could have a material adverse effect on our business. Manufacturing of biological compounds
is inherently complex and establishing new manufacturing relationships with a third party manufacturer may take longer, resulting
in higher costs and potential inventory issues. Manufacturing processes may use materials which Summit may not be able to secure,
requiring Summit to have to develop alternative processes and delay manufacturing. The product may not comply with the FDA quality
requirements and/or have sufficient stability for commercialization, which may require additional manufacturing development and
delays. As Summit is relying initially on supply from Akeso, any delays in obtaining import or export licenses may delay start
of clinical trials.
If
clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the U.S. Food and Drug
Administration, or the FDA, or the European Medicines Agency, or the EMA, or do not otherwise produce favorable results, we may
incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization
of ivonescimab or any other product candidate.
In
connection with obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical
development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical
testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. A
failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials
may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final
results. In particular, due to the small number of patients in our early clinical trials, results from such trials may not be predictive
of the outcome of later clinical trials. The design of a clinical trial can determine whether its results will support approval of a
product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced or completed.
We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing
approval. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that
have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to
obtain marketing approval of their products.
To date, we have not conducted a clinical trial for ivonescimab and cannot predict the results
of such trials.
If
we experience delays or difficulties in the enrollment of patients in our clinical trials, our receipt of necessary marketing
approvals could be delayed or prevented.
We
may not be able to initiate or continue clinical trials for our product candidates, if we are unable to locate and enroll a sufficient
number of eligible patients to participate in these clinical trials.
Patient
enrollment is affected by other factors, including:
| ● | severity
of the disease under investigation; |
| ● | eligibility
criteria for the clinical trial in question; |
| ● | perceived
risks and benefits of the product candidate under study; |
| ● | competition
for patients, time and resources at clinical trials sites from other investigational
therapies in clinical trials that target the same patient population; |
| ● | approval
of other therapies to treat the indication that is being investigated in the clinical
trial; |
| ● | efforts
to facilitate timely enrollment in clinical trials; |
| ● | patient
referral practices of physicians; |
| ● | the
ability to monitor patients adequately during and after treatment; and |
| ● | proximity
and availability of clinical trial sites for prospective patients. |
Enrollment
delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value
of our company to decline and limit our ability to obtain additional financing. Our inability to enroll a sufficient number of
patients in a clinical trial for ivonescimab or any other planned clinical trials would result in significant delays, may generate
a limited data set from which no meaningful conclusions could be made, or may require us to abandon one or more clinical trials
altogether.
If
serious adverse or inappropriate side effects are identified during the development of ivonescimab or any other product candidate,
we may need to abandon or limit our development of that product candidate.
All
of our product candidates are in clinical or early-stage development and their risk of failure is high. It is impossible to predict
when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval. If our product
candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon their
development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics
are less prevalent, less severe or more acceptable from a risk-benefit perspective.
Many
compounds that initially showed promise in clinical or earlier stage testing have later been found to cause side effects or other
safety issues that prevented further development of the compound. If we elect or are forced to suspend or terminate any clinical
trial of our product candidates, the commercial prospects of such product candidate will be harmed and our ability to generate
product revenues from such product candidate will be delayed or eliminated. Any of these occurrences could materially harm our
business.
The
Committee on Foreign Investment in the United States (“CFIUS”) or other regulatory agencies may modify, delay or prevent
the transactions contemplated by the License Agreement.
The
Committee on Foreign Investment in the United States (“CFIUS”) has authority to review direct or indirect foreign
investments in U.S. companies. Among other things, CFIUS is empowered to require certain foreign investors to make mandatory filings,
to charge filing fees related to such filings and to self-initiate national security reviews of foreign direct and indirect investments
in U.S. companies if the parties to that investment choose not to file voluntarily. In the case that CFIUS determines an investment
to be a threat to national security, CFIUS has the power to unwind or place restrictions on the investment. Whether CFIUS has
jurisdiction to review an acquisition or investment transaction depends on, among other factors, the nature and structure of the
transaction, including the level of beneficial ownership interest and the nature of any information or governance rights involved.
For example, investments that result in “control” of a U.S. business by a foreign person always are subject to CFIUS
jurisdiction. CFIUS’s expanded jurisdiction under the Foreign Investment Risk Review Modernization Act of 2018 and implementing
regulations that became effective on February 13, 2020 further includes investments that do not result in control of a U.S. business
by a foreign person but afford certain foreign investors certain information or governance rights in a U.S. business that has
a nexus to “critical technologies,” “critical infrastructure” and/or “sensitive personal data.”
We
believe that no mandatory filing was required in connection with the License Agreement but we have not yet determined whether
we will make a voluntary filing. CFIUS may decide to modify or delay our proposed business combination, impose conditions with
respect to such business combination, request the President of the United States to order us to divest all or a portion of the
assets we acquired without first obtaining CFIUS approval or prohibit the License Agreement entirely. If it is determined that
a mandatory filing was required to be made, it is possible that a material penalty could be assessed against the Company.
We
may complete a future acquisition that may not achieve intended results or could increase the number of our outstanding shares
or amount of outstanding debt or result in a change of control.
In
addition to the License Agreement and the transactions contemplated thereby, we may pursue business development opportunities
to expand or enhance our pipeline of drug candidates, including without limitation, through potential acquisitions of and/or collaborations
with other entities. Any such transaction could happen at any time, could be material to our business and could take any number
of forms, including, for example, an acquisition, merger or a collaboration with other entities.
Evaluating
potential transactions and integrating completed ones may divert the attention of our management from ordinary operating matters.
The success of these potential transactions will depend, in part, on our ability to realize the anticipated growth opportunities
through the successful integration of the businesses we acquire with our existing business, as well as the success of the underlying
business or intellectual property that we acquire or otherwise obtain rights to. Even if we are successful in integrating the
acquired businesses, these integrations may not result in the realization of the full benefit of any anticipated growth opportunities
or these benefits may not be realized within the expected time frames. In addition, acquired businesses may have unanticipated
liabilities or contingencies.
If
we complete an acquisition, investment or other strategic transaction, we may require additional financing that could result in
an increase in the number of our outstanding shares or the aggregate amount of our debt.
We
will need substantial additional capital to fund our operations and to make payments under the License Agreement and the Note
Purchase Agreement and if we fail to obtain necessary financing, we could be forced to delay, reduce or eliminate the development
and commercialization of our product candidates.
Conducting
preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and
we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition,
our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from
sales of products that we are not planning to have commercially available for several years, if at all. Accordingly, we will need
to continue to rely on additional financing to achieve our business objectives. In addition, we may seek additional capital due
to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or
future operating plans. Additional financing may not be available to us on acceptable terms, or at all.
We
expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly
in connection with the License Agreement. In addition, if we obtain marketing approval these potential future product candidates
where we retain commercial rights or any other product candidates we develop, we expect to incur significant commercialization
expenses related to product sales, marketing, distribution and manufacturing. Accordingly, we will need to obtain substantial
additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive
terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization
efforts.
Our
primary future capital requirements will be related to our obligations under the License Agreement.
We
expect to continue to generate operating losses for the foreseeable future. The License Agreement calls for initial consideration
payments of $500 million, as well as total contingent payments by the Company of up to $5.0 billion, as Akeso will be eligible
to receive regulatory milestones of up to $1.05 billion and commercial milestones of up to $3.45 billion, many of which will be
due before the Company anticipates generating any revenue from the License Agreement. We entered into the Note Purchase Agreement
to fund the initial consideration payments and we will need additional capital to fund our operations and payments under the License
Agreement and the Note Purchase Agreement. $420 million of the proceeds of the Rights Offering are anticipated to be used to repay
borrowings under the Note Purchase Agreement. We also anticipate further capital raises to repay the remaining borrowings under
the Note Purchase Agreement. We do not have any committed external sources of funds and do not anticipate receiving any additional
funds from BARDA with respect to SMT112. Under this Rights Offering, Mr. Robert W. Duggan and Dr. Mahkam Zanganeh have each indicated
that they intend to participate in the Rights Offering and subscribe for at least the full amount of their Basic Subscription
Rights, but they have not made any formal binding commitment to participate. We will need to seek additional funding in the future
to fund operations. Additional capital, when needed, may not be available to us on acceptable terms, or at all. To the extent
that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing
stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect
the rights of our existing stockholders. Debt financing, if available, may involve agreements that include covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring
dividends or other distributions. If we raise additional funds through collaborations, strategic alliances or marketing, distribution,
or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams,
research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise
sufficient funds through this Rights Offering or other equity, debt financings, or other arrangements when needed based on our
liquidity needs, we may implement an alternative operating plan that materially scales back our operations, reduces cash expenditures,
and focuses our available capital on a reduced number of activities and programs.
In January 2023, the Company provided notice to Mr. Duggan that it has elected to extend the Maturity Dates of the $400 million February
Note and the September Note to September 6, 2024. By
extending the Notes to the final maturing date, the Company’s cash, cash equivalents and U.K. research and development tax credits
would be sufficient to fund our operations into the second half of 2024.
We
have substantial indebtedness and will likely require additional indebtedness in the future, which may require us to use a substantial
portion of our cash flow to service debt and limit our financial and operating flexibility.
We
have substantial indebtedness and will likely require additional indebtedness in the future. As of [●], we had a total of
$520 million of indebtedness outstanding under the Note Purchase Agreement. Upon the completion of this Rights Offering, after
giving effect to the use of proceeds described in this prospectus, we expect to have repaid $420 million of indebtedness outstanding
under the Note Purchase Agreement. Further, the License Agreement calls for certain additional future payment obligations and
we may require additional indebtedness to fund those obligations. Our existing and future indebtedness will require interest payments
and need to be repaid or refinanced and could require us to divert funds identified for other purposes to service our debt, could
result in cash demands and impair our liquidity position and could result in financial risk for us. Diverting funds identified
for other purposes for debt service may adversely affect our growth prospects. If we cannot generate sufficient cash flow from
operations to service our debt, we may need to refinance our debt, dispose of assets, or issue equity to obtain necessary funds.
We do not know whether we would be able to take any of these actions on a timely basis, on terms satisfactory to us, or at all.
The
Company’s failure to comply with the terms and obligations of the Note Purchase Agreement, including as a result of events
beyond our control, may result in an event of default.
The
Note Purchase Agreement requires us to comply with certain repayment obligations, representations and covenants. For a more detailed
discussion, see “Prospectus Summary — Other Material Agreements” beginning on page 21. A breach of any
of these obligations, representations or covenants or the occurrence of certain other specified events could result in an event
of default under the Note Purchase Agreement. Upon the occurrence of any event of default under the Note Purchase Agreement, the
outstanding balance on the corresponding Note will, at the option of such lender, become immediately and automatically due and
payable in cash and a default interest rate of an additional 2% per annum will apply on all outstanding obligations during the
occurrence and continuance of an event of default.
We
may not be able to maintain compliance with these repayment obligations and covenants in the future and, if we fail to do so,
that we may not able to obtain waivers from the lenders and/or amend the covenants. Our failure to comply with the repayment obligations
and covenants described above could result in an event of default, which, if not cured or waived, and if lender accelerates, would
result in us being required to repay these borrowings before their due date. If we are forced to refinance these borrowings on
less favorable terms or if we are unable to refinance these borrowings, our business, financial condition, and results of operations
could be materially adversely affected.
We
are a development-stage company and have incurred significant losses since our inception. We expect to incur losses for at least
the next several years and may never generate profits from operations or maintain profitability.
We
are a development-stage company and we cannot assure profitability. We expect to continue to generate operating losses for the
foreseeable future. Until we can generate substantial revenue and achieve profitability, we will need to raise additional capital
to fund ongoing operations and capital needs. Since inception, we have incurred significant operating losses. In the year ended
December 31, 2021, we incurred a net loss of $88,602. In the three months ended September 30, 2022, we incurred net losses of
$21,385. These losses could continue for the next several years as we invest in clinical development of ivonescimab. We believe
that our existing cash, cash equivalents and U.K. research and development tax credits, together with the net proceeds from this
Rights Offering, will fund our operations and initially planned clinical trials for ivonescimab into the second half of 2024.
To
become and remain profitable, we must succeed in developing and eventually either commercializing or partnering with other organizations
to commercialize products that generate significant revenue. This will require us to be successful in a range of challenging activities,
including completing preclinical testing and clinical trials of our product candidates, discovering additional product candidates,
obtaining regulatory approval for these product candidates and manufacturing, marketing, and selling any products for which we
may obtain regulatory approval. We are in the preliminary stages of many of these activities. We may never succeed in these activities
and, even if we do, may never generate revenue that is significant enough to achieve profitability.
Because
of the numerous risks and uncertainties associated with pharmaceutical products and biological development, we are unable to accurately
predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability.
Even
if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure
to become and remain profitable would depress our value and could impair our ability to raise capital, expand our business, maintain
our research and development efforts, diversify our product offerings or even continue our operations.
Our
business is subject to the risks associated with doing business in China.
As
a result of our reliance on Akeso, located in China, our results of operations, financial condition, and prospects are subject
to a significant degree to economic, political, and legal developments in China including government control over capital investments
or changes in tax regulations that are applicable to us. China’s economy differs from the economies of most developed countries
in many respects, including with respect to the amount of government involvement, level of development, growth rate and control
of foreign exchange, and allocation of resources. Since we rely on an entity located in China, our business is subject to the
risks associated with doing business in China, including:
| ● | adverse
political and economic conditions, particularly those potentially negatively affecting
the trade relationship between the United States and China; |
| ● | trade
protection measures, such as tariff increases, and import and export licensing and control
requirements; |
| ● | potentially
negative consequences from changes in tax laws; |
| ● | difficulties
associated with the Chinese legal system, including increased costs and uncertainties
associated with enforcing contractual obligations in China; |
| ● | historically
lower protection of intellectual property rights; |
| ● | requirements
relating to China’s data security rules and regulations; |
| ● | changes
and volatility in currency exchange rates; |
| ● | unexpected
or unfavorable changes in regulatory requirements; and |
| ● | difficulties
in managing foreign relationships and operations generally. |
U.S.-China trade
relations may adversely impact our supply chain operations and business.
The
U.S. and Chinese governments have taken certain actions that change trade policies, including tariffs that affect certain products
which are manufactured in China and mutual exchange of certain types of data. Due to our collaboration with Akeso, we are reliant
on collaborating with a company with significant operations in China. It is unknown whether and to what extent new tariffs, laws
or regulations will be adopted that increase the cost or feasibility of importing and/or exporting products, components and information
from China to the United States and vice versa. Further, the effect of any such new tariffs or actions on our industry and
customers is unknown and difficult to predict. As additional new tariffs, legislation and/or regulations are implemented, or if
existing trade agreements are renegotiated or if China or other affected countries take retaliatory trade actions, such changes
could have a material adverse effect on our clinical development plans, business, financial condition, results of operations or
cash flows.
Risks
Related to this Rights Offering and the Ownership of the Common Stock
The
Subscription Price determined for this Rights Offering is not an indication of our value.
In
determining the Subscription Price for the Rights Offering, the Special Committee considered a number of factors, including: the
likely cost of capital from other sources and general conditions of the securities markets, the price at which our stockholders
might be willing to participate in the Rights Offering, our need for liquidity and capital, the average price for the 30-day period
prior to the filing of the preliminary Proxy Statement on November 29, 2022, and the desire to provide an opportunity to our
stockholders to participate in the Rights Offering on a pro rata basis. The Special Committee determined that it was in the best
interests of the Company’s stockholders to publicly announce the Initial Price and the Alternate Price so that all
stockholders had the opportunity to determine whether to buy or sell the Company’s shares of common stock prior to the Record
Date. The Company did not consider revising the Initial Price. The Company believes this disclosure has provided its stockholders
and the public with sufficient information about the Company’s expectation to sell a significant number of shares in the
Rights Offering, as described herein. The Subscription Price is not necessarily related to our book value, net worth or any other
established criteria of value and may or may not be considered the fair value of the common stock to be offered in the Rights
Offering. The market price of our common stock may decline during or after the Rights Offering, including below the applicable
Subscription Price. After the date of this prospectus, our common stock may trade at prices above or below the Subscription
Price.
This
Rights Offering may cause the trading price of our common stock to decrease.
The
Subscription Price, together with the number of the common stock we propose to issue and ultimately will issue if this Rights
Offering is completed, may result in an immediate decrease in the market price of our common stock. This decrease may continue
after the completion of this Rights Offering. If that occurs, you may have committed to buy common stock in the Rights Offering
at a price greater than the prevailing market price. The Alternate Price provides certain protection in the event that the market
price declines after subscription but immediately prior to the expiration of the Rights Offering. However, it is possible that
the Alternate Price may be higher than the market price at the time you receive your shares. Your subscription is not revocable.
Once you submit your subscription, even if the market price declines, you will not be able to revoke your subscription. Given
that the Board reserves the right to terminate the Rights Offering at any time, the Special Committee and Board determined that
a floor price was not in the best interests of the Company. Following the closing of the Rights Offering, if a substantial number
of Subscription Rights are exercised and the holders of the shares received upon exercise of those Subscription Rights choose
to sell some or all of the shares underlying the Subscription Rights, the resulting sales could depress the market price of our
common stock. Following the exercise of your Subscription Rights you may not be able to sell your common stock at a price equal
to or greater than the Subscription Price.
The
price of our common stock may be volatile.
The
trading price of our common stock may fluctuate significantly. The price of our common stock that will prevail in the market after
this Rights Offering may be higher or lower than the Subscription Price depending on many factors, some of which are beyond our
control and may not be directly related to our operating performance. These factors include, but are not limited to, the following:
| ● | The
terms of any potential future transaction(s) related to debt financing, debt restructuring
or capital raising; |
| ● | developments
in our relationships with employees, suppliers, distributors, sales representatives and
customers; |
| ● | acquisitions
or divestitures; |
| ● | litigation
and government proceedings; |
| ● | adverse
legislation, including changes in governmental regulation; |
| ● | additions
or departures of key personnel; |
| ● | sales
of our equity securities by our significant stockholders or management or sales of additional
equity securities by our company; |
| ● | changes
in securities analysts’ recommendations; |
| ● | economic
and other external factors; and |
| ● | general
market conditions. |
Additionally,
the stock market historically has experienced significant price and volume fluctuations. These fluctuations are often unrelated
to the operating performance of particular companies. These broad market fluctuations, such as those caused by the COVID-19 pandemic,
may cause declines in the trading price and market value of our common stock.
We
have received the requisite approvals and if the Board decides to proceed with the reverse stock split after the closing
of the Rights Offering and issuance of shares thereunder, it may decrease the liquidity of the shares of our common stock and
could lead to a decrease in our overall market capitalization.
While
the Board reserves the right to effect the reverse stock split prior to January 6, 2024, we do not intend to effect the reverse
stock split prior to the closing of the Rights Offering and issuance of shares thereunder. The liquidity of the shares of our
common stock may be affected adversely by such reverse stock split given the reduced number of shares of our common
stock that will be outstanding following such reverse stock split, especially if the market price of our common
stock does not increase as a result of such reverse stock split. In addition, such reverse stock split may
increase the number of stockholders who own odd lots (less than 100 shares) of our common stock, creating the potential for such
stockholders to experience an increase in the cost of selling their shares of common stock and greater difficulty effecting such
sales.
We
expect that the proposed reverse stock split, if effected, will increase the per share trading price of our common stock. However,
the market price per share of our common stock after the reverse stock split may not rise (or remain constant) in proportion to
the reduction in the number of shares of common stock outstanding before the reverse stock split. We cannot predict the effect
of the reverse stock split on the per share trading price of our common stock, and the history of reverse stock splits for other
companies is varied, particularly since some investors may view a reverse stock split negatively. Our total market capitalization
after the reverse stock split, if approved and effective, may be lower than our total market capitalization before the reverse
stock split.
There is no guarantee that by the time the shares are delivered to you, the market price of our common stock will be above
the Subscription Price for such shares. Further, because the exercise of your Subscription Rights is not revocable and because
the rights are not transferable, you will not be able to revoke your subscription if the market price decreases prior to the delivery
of the shares or transfer of the shares until after they are delivered.
There
is no guarantee that the Subscription Price, whether it is set at the Initial Price or the Alternate Price, will be lower than
the market price of our common stock at the time that the shares that you receive in the Rights Offering are delivered. Further,
because the exercise of your Subscription Rights is not revocable and because the rights are not transferable, you will not be
able to revoke your subscription if the market price decreases prior to the delivery of the shares or transfer of the shares until
after they are delivered to you. Accordingly, the Subscription Price at which you are purchasing shares of common stock may be
above the prevailing market price by the time that the shares of common stock are purchased and delivered.
If
you exercise your Subscription Rights and the market price of the common stock falls below the Subscription Price, then you will
have committed to subscribe in the Rights Offering at a price that is higher than the market price. Moreover, we may never be
able to sell shares of common stock that you received in the Rights Offering at a price equal to or greater than the Subscription
Price or exercise price. Until shares are issued to you in book-entry, or uncertificated, form upon expiration of the Rights Offering,
you may not be able to sell the shares of our common stock that you receive in the Rights Offering. We will issue shares of our
common stock that you received in the Rights Offering in book-entry, or uncertificated, form as soon as practicable after expiration
of the Rights Offering. We will not pay you interest on funds delivered to the subscription agent pursuant to the exercise of
rights.
If
you do not exercise your Subscription Rights in full, your percentage ownership and voting rights in Summit will experience dilution.
If
you choose not to exercise your Subscription Rights, you will retain your current number of shares of our common stock. If other
stockholders fully exercise their Subscription Rights or exercise a greater proportion of their Subscription Rights than you exercise,
the percentage of our common stock owned by these other stockholders will increase relative to your ownership percentage, and
your voting and other rights in the Company will likewise be diluted.
The
Subscription Rights are non-transferable and thus there will be no market for them.
You
may not sell, transfer or assign your Subscription Rights to anyone else, unless as required by operation of law. We do not intend
to list the Subscription Rights on the Nasdaq or any securities exchange or trading market. Because the Subscription Rights are
non-transferable, there is no market or other means for you to directly realize any value associated with the Subscription Rights.
You
may not be able to resell any shares of our common stock that you receive pursuant to the exercise of Subscription Rights immediately
upon expiration of the Subscription Rights Offering period or be able to sell your shares at a price equal to or greater than
the Subscription Price.
If
you exercise Subscription Rights, you may not be able to resell the common stock that you receive in the Rights Offering until
you, or your custodian bank, broker, dealer or other nominee, if applicable, have received those shares. Moreover, you will have
no rights as a stockholder of the shares you received in the Rights Offering until we issue the shares to you. Although we will
endeavor to issue the shares as soon as practicable after completion of the Rights Offering, and after all necessary calculations
have been completed, there may be a delay between the Expiration Date of the Rights Offering and the time that the shares are
issued. In addition, following the exercise of your Subscription Rights, you may not be able to sell your common stock at a price
equal to or greater than the Subscription Price.
Because
no minimum subscription is required and because we do not have formal commitments from our stockholders for the entire amount
we seek to raise pursuant to the Rights Offering, we cannot assure you of the amount of proceeds that we will receive from the
Rights Offering.
No
minimum subscription is required for consummation of the Rights Offering. Although Robert W. Duggan, our Executive Chairman, Chief
Executive Officer, and the beneficial owner of approximately 78.1% of our common stock prior to this Rights Offering, and Dr.
Mahkam Zanganeh, our co-Chief Executive Officer, President, a member of our Board of Directors, and the beneficial owner of approximately
6.0% of our common stock prior to this Rights Offering, have each indicated that they intend to participate in the Rights Offering
and subscribe for at least the full amount of their Basic Subscription Rights, but have not made any formal binding commitment
to participate. It is also possible that no Over-Subscription Rights will be exercised in connection with the Rights Offering.
As a result, we cannot assure you of the amount of proceeds that we will receive in the Rights Offering. Therefore, if you exercise
all or any portion of your Subscription Rights, but other stockholders do not, we may not raise the desired amount of capital
in the Rights Offering, the market price of our common stock could be adversely impacted and we may find it necessary to pursue
alternative means of financing, which may be dilutive to your investment.
Because
we may terminate the Rights Offering at any time prior to the Expiration Date, your participation in the Rights Offering is not
assured.
We
do not intend, but have the right, to terminate the Rights Offering at any time prior to the Expiration Date. If we determine
to terminate the Rights Offering, we will not have any obligation with respect to the Subscription Rights except to return any
money received from subscribing stockholders as soon as practicable, without interest or deduction.
You
will need to act promptly and carefully follow the subscription instructions, or your exercise of rights may be rejected.
Stockholders
who desire to subscribe for shares of common stock in the Rights Offering must act promptly to ensure that all required forms
and payments are actually received by the subscription agent prior to the Expiration Date, which is currently set to be 5:00 p.m.
on [●]. If you are a beneficial owner of shares, you must act promptly to ensure that your custodian bank, broker, dealer
or other nominee acts for you and that all required forms and payments are actually received by the subscription agent prior to
the Expiration Date. Your nominee may establish a deadline prior to the Expiration Date by which you must provide it with your
instructions to exercise your Subscription Rights and payment for your shares of common stock. We will not be responsible if your
custodian bank, broker, dealer or nominee fails to ensure that all required forms and payments are actually received by the subscription
agent prior to the Expiration Date. If you fail to complete and sign the required subscription forms, send an incorrect payment
amount, or otherwise fail to follow the subscription procedures that apply to your desired transaction the subscription agent
may, depending on the circumstances, reject your subscription or accept it to the extent of the payment received. Neither we nor
our subscription agent will undertake to contact you concerning, or attempt to correct, an incomplete or incorrect subscription
form or payment. We have the sole discretion to determine whether a subscription exercise properly follows the subscription procedures.
By
participating in the Rights Offering and executing a rights certificate, you are making binding and enforceable representations
to the Company.
By
signing the rights certificate and exercising their rights, each stockholder agrees, solely with respect to such stockholder’s
exercise of rights in the Rights Offering, that we have the right to void and cancel (and treat as if never exercised) any exercise
of rights, and securities issued pursuant to an exercise of rights, if any of the agreements, representations or warranties of
a subscriber in the subscription documents are false.
If
you exercise the Over-Subscription Right, you may not receive all of the shares of common stock for which you subscribe.
Exercise
of the Over-Subscription Right will only be honored if and to the extent that the Basic Subscription Rights have not been exercised
in full. If a sufficient number of shares of common stock are available, we will seek to honor your over-subscription request
in full. If, however, over-subscription requests exceed the number of shares available to be purchased pursuant to the Over-Subscription
Right, we will allocate the available share proportionately among stockholders who exercised their Over-Subscription Rights based
on the number of shares each stockholder subscribed for under such stockholder’s Basic Subscription Rights. As a result,
you may not receive any or all of the shares of common stock for which you exercise your Over-Subscription Right.
As
soon as practicable after the Expiration Date, the subscription agent will determine the number of shares of common stock that
you may purchase pursuant to the Over-Subscription Right. If you have properly exercised your Over-Subscription Right, we will
issue the shares of common stock purchased in the Rights Offering to you in book-entry, or uncertificated, form as soon as practicable
after the Expiration Date and after all allocations and adjustments have been effected. If you request and pay for more shares
than are allocated to you, we will refund the overpayment, without interest or deduction. In connection with the exercise of the
Over-Subscription Right, custodian banks, brokers, dealers and other nominee holders of Subscription Rights who act on behalf
of beneficial owners will be required to certify to us and to the subscription agent as to the aggregate number of Subscription
Rights exercised, and the number of shares requested through the Over-Subscription Right, by each beneficial owner on whose behalf
the nominee holder is acting.
The
tax treatment of the Rights Offering may be treated as a taxable event to you.
We
believe and intend to take the position that the distribution of the Subscription Rights in connection with the Rights Offering
generally should not be a taxable event to U.S. holders of our common stock for U.S. federal income tax purposes. However, if
the distribution of rights (or a series of distributions of which this distribution is one) were deemed to be a “disproportionate
distribution” under Section 305(b)(2) of the Internal Revenue Code of 1986, as amended (the “Code”), holders
of our common stock may recognize taxable income for U.S. federal income tax purposes in connection with the receipt of Subscription
Rights in the Rights Offering. Holders of our common stock are urged to consult their own tax advisors with respect to the tax
consequences of the Rights Offering. Please see the section titled “Material U.S. Federal Income Tax Consequences”
beginning on page 48 for further information.
We
have broad discretion in the use of the net proceeds from this Rights Offering and may use them in a manner that does not improve
our financial performance or operating results.
We
currently intend to use the net proceeds from this Rights Offering, after deducting our offering expenses, for one or more of
the following purposes: (i) the repayment of certain unsecured promissory notes totaling $420 million issued pursuant to the Note
Purchase Agreement and (ii) general corporate purposes, which includes funding the Company’s activities to support clinical
development and regulatory approval for SMT112 and pursue business development opportunities to expand or enhance our pipeline
of drug candidates. For a more detailed discussion, see “Use of Proceeds” beginning on page 35. Although we
plan to use the net proceeds from this Rights Offering as described, we have not designated the amount of net proceeds from this
Rights Offering to be used for any specific purpose. We will have broad discretion in the use of the net proceeds. You will be
relying on the judgment of our management regarding the application of the proceeds of this Rights Offering. The results and effectiveness
of the use of proceeds are uncertain, and we could spend the proceeds in ways that you do not agree with or that do not improve
our results of operations or enhance the value of our common stock.
If
our common stock trades below $1.00, we may fail to meet the continued listing requirements of the Nasdaq Global Market and our
common stock may be delisted.
Our
common stock is subject to certain continued listing standards set by the Nasdaq Global Market, including a requirement to maintain
a minimum bid price of at least $1.00 per share. If our common stock fails to meet such standards, it could be delisted from the
Nasdaq Global Market. This would have a negative impact on the liquidity of our common stock, including shares subscribed for
in this Rights Offering.
USE
OF PROCEEDS
Although
we cannot determine what the actual net proceeds from the sale of common stock in the Rights Offering will be until the Rights
Offering is completed, assuming all Subscription Rights are exercised, we estimate that the aggregate net proceeds from the sale
of the common stock, after deducting estimated offering expenses, will be approximately $499.5 million.
We
currently intend to use the net proceeds from this Rights Offering, after deducting our offering expenses, for one or more of
the following purposes: (i) the repayment of certain unsecured promissory notes totaling $420 million issued pursuant to the Note
Purchase Agreement and (ii) general corporate purposes, which includes funding the Company’s activities
to support clinical development and regulatory approval for SMT112 and pursue business development opportunities to expand or
enhance our pipeline of drug candidates. We have not determined the amount of net proceeds to be used for any specific
purpose, and management will retain broad discretion over the allocation of net proceeds. While we have no current agreements,
commitments or understandings for any specific acquisitions at this time other than the License Agreement, we may use a portion
of the net proceeds for these purposes. We believe that our existing cash, cash equivalents and U.K. research and development
tax credits, together with the net proceeds from this Rights Offering, will fund our operations and initially planned clinical
trials for ivonescimab into the second half of 2024.
As
previously disclosed, on December 6, 2022, we entered into the Note Purchase Agreement and
promissory notes with Robert W. Duggan, the Company’s Chief Executive Officer, Chairman of the Board, and beneficial owner
of approximately 78.1% of the Company’s common stock and Dr. Mahkam Zanganeh, the Company’s co-Chief Executive Officer,
President, member of the Board and beneficial owner of approximately 6.0% of the Company’s common stock. Pursuant to the
Note Purchase Agreement, the Company agreed to sell to Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate
amount of $520 million for the principal purpose of funding the Company’s initial payment obligations under the License
Agreement. The Company expects to use the proceeds of the Note Purchase Agreement to support
(i) payment of the upfront obligation totaling $500 million associated with the License Agreement as described herein; (ii) activities
to support clinical development and regulatory approval for SMT112; (iii) pursue business development opportunities to expand
or enhance our pipeline of drug candidates; and (iv) general corporate purposes.
This
expected use of the net proceeds from this Rights Offering represents our intentions based upon our current plans and business
conditions and numerous factors, including the factors described under “Risk Factors.” As of the date of this
prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion
of this Rights Offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our
actual expenditures and the use of these proceeds may vary significantly depending on numerous factors, including the progress
of our expansion efforts and acquisition activities, as well as any unforeseen cash needs. As a result, our management will retain
broad discretion over the allocation of the net proceeds from this Rights Offering.
CAPITALIZATION
The
following table sets forth our capitalization as of September 30, 2022 to reflect the following:
| ● | on
an actual basis per our Form 10-Q for the quarter ended September 30, 2022, which is
incorporated into this prospectus by reference; |
| ● | on an adjusted basis to give effect to the following events, as if each event had occurred on September 30, 2022: (i) $520 million in
proceeds of the Note Purchase Agreement, offset by $7.7 million of prepaid interest which represents the value of the shares issued in
connection with the Note Purchase Agreement, (ii) the issuance of 9,346,434 and 373,857 shares for the prepaid interest to Robert W. Duggan
and Dr. Mahkam Zanganeh, respectively, in connection with the Note Purchase Agreement and (iii) the first installment payment to Akeso
for the upfront payment pursuant to the License Agreement, of which Akeso opted to receive 10 million shares of Summit common stock with
a fair value on the Antitrust Clearance Date and $274.9 million was paid to Akeso in cash; and |
| ● | on a pro forma as adjusted basis giving further effect to the following events (i) the first installment payment of $300 million in cash
to Akeso for the upfront payment pursuant to the License Agreement, (i) the issuance of 476,190,476 common stock in the Rights Offering,
assuming the exercise of all of the Subscription Rights at a Subscription Price of $1.05 per common stock with aggregate net proceeds
of approximately $499.5 million, after deducting our payment of estimated offering expenses and (ii) repayment of certain unsecured promissory
notes totaling $420 million issued pursuant to the Note Purchase Agreement with proceeds of the Rights Offering and recognition of the
$7.7 million of prepaid interest. |
The
following table does not consider the second upfront payment due to Akeso of $200 million pursuant to the License Agreement, as
this is expected to be paid after the consummation of the Rights Offering.
The
information presented in the table below should be read in conjunction with “Management’s Discussion and Analysis
of Financial Condition and Results of Operations” and the historical consolidated financial statements and notes thereto
included in our Form 10-Q for the quarter ended September 30, 2022, which is incorporated into this prospectus by reference.
| |
As of September 30, 2022 |
| |
As reported | |
As adjusted | |
Pro Forma
As Adjusted |
| |
(U.S. dollars in thousands) Unaudited |
Cash and cash equivalents | |
| 121,971 | | |
| 367,071 | | |
| 446,571 | |
Total current assets | |
| 137,119 | | |
| 382,219 | | |
| 461,719 | |
Debt | |
| — | | |
| 512,308 | | |
| 100,000 | |
Shareholders' Equity | |
| | | |
| | | |
| | |
Preferred stock, $0.01 par value, 20,000,000 shares authorized; no shares issued or outstanding actual or as adjusted | |
| — | | |
| — | | |
| — | |
Common stock, $0.01 par value, 350,000,000 shares authorized; 201,321,175 issued and
outstanding actual; 1,000,000,000 shares authorized as adjusted; 221,041,466 issued and outstanding as adjusted; 1,000,000,000
shares authorized as pro forma adjusted; 697,231,942 issued and outstanding as pro forma adjusted | |
| 2,013 | | |
| 2,210 | | |
| 6,972 | |
Additional paid-in capital | |
| 493,553 | | |
| 546,947 | | |
| 1,041,686 | |
Accumulated other comprehensive income (loss) | |
| (3,217 | ) | |
| (3,217 | ) | |
| (3,217 | ) |
Accumulated deficit | |
| (359,101 | ) | |
| (679,101 | ) | |
| (687,593 | ) |
Total shareholders' equity | |
| 133,248 | | |
| 133,960 | | |
| 357,848 | |
DILUTION
Our
net tangible book value as of September 30, 2022 was approximately $123.6 million, or $0.61 per share of our common stock. Net
tangible book value per share is equal to our total net tangible book value, which is our total tangible assets less our total
liabilities, divided by the number of shares of our outstanding common stock. Dilution per share equals the difference between
the amount per share paid by purchasers of shares of common stock that are sold in the Rights Offering and the net tangible book
value per share of our common stock immediately after the Rights Offering.
After
giving effect to the assumed sale of 476,190,476 shares of our common stock in the Rights Offering, based on the assumed Subscription
Price of $1.05 per shares of common stock, and after deducting estimated offering expenses payable by us, our pro forma net tangible
book value as of September 30, 2022 would have been approximately $623.1 million, or $0.92 per share. This represents an immediate
increase in pro forma net tangible book value to existing stockholders of $0.31 per share and an immediate dilution to purchasers
in the Rights Offering of $0.13 per share.
The
following table illustrates this per-share dilution, assuming the Rights Offering is fully subscribed at the assumed Subscription
Price of $1.05 per share of common stock. To the extent that the Alternate Price is lower than the Initial Price, purchasers of
our common stock in the Rights Offering will experience further dilution.
Assumed Subscription Price per share | |
| | | $ |
1.05 |
|
Net tangible book value per share as of September 30, 2022 | |
$ | 0.61 | |
|
|
|
Increase in net tangible book value per share attributable to this Rights Offering | |
$ | 0.31 | |
|
|
|
Net tangible book value per share as of September 30, 2022, after giving effect to this Rights Offering | |
| | | $ |
0.92 |
|
Dilution per share to investors purchasing shares in this Rights Offering | |
| | | $ |
0.13 |
|
The
information above is illustrative only and will adjust based on the actual Subscription Price and the actual number of shares
of common stock sold in the Rights Offering. The number of shares to be outstanding after this Rights Offering is based on 201,321,175
shares of common stock outstanding at September 30, 2022 and does not give effect to:
| ● | the
exercise of outstanding warrants to purchase 5,821,137 shares of common stock at a weighted-average
exercise price of $1.56; |
| ● | the
exercise of outstanding options to purchase 19,660,009 shares of common stock at a weighted-average
exercise price of $3.59; |
| ● | the
issuance of 9,346,434 shares of common stock issued to Mr. Duggan in connection with
the Note Purchase Agreement, dated December 6, 2022, between the Company, Mr. Duggan
and Dr. Zanganeh; |
| ● | the
issuance of 373,857 shares of common stock issued to Dr. Zanganeh in connection with
the Note Purchase Agreement, dated December 6, 2022, between the Company, Mr. Duggan
and Dr. Zanganeh; |
| ● | the issuance of 10,000,000 shares of common stock issued to Akeso, Inc in connection with the Common Stock Issuance Agreement, dated January
17, 2023, between the Company and Akeso, Inc. |
| ● | the
issuance of up to 5,545,818 shares of common stock reserved for future issuance under
our 2020 Stock Incentive Plan; and |
| ● | the
issuance of up to 2,628,893 shares of common stock reserved for future issuances under
our 2020 Employee Share Purchase Plan. |
Furthermore,
we may choose to raise additional capital through the sale of equity or equity-linked securities due to market conditions or strategic
considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that any
of our outstanding warrants or options are exercised or we issue additional shares of common stock or other equity or equity-linked
securities in the future, there may be further dilution to investors participating in this Rights Offering. This information does
not reflect the annual increases provided under the 2020 Stock Incentive Plan and 2020 Employee Stock Purchase Plan, which have
not yet been determined by the Board.
DESCRIPTION
OF CAPITAL STOCK
The
following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital
stock. This description is based upon, and is qualified by reference to, our restated certificate of incorporation, our amended
and restated bylaws and applicable provisions of Delaware corporate law. You should read our restated certificate of incorporation
and amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus forms a part,
for the provisions that are important to you.
Our
authorized capital stock consists of 1,000,000,000 shares of common stock, $0.01 par value per share and 20,000,000 shares of
preferred stock, $0.01 par value per share. As of the Record Date, the Company had 221,241,725 shares of common stock issued and
outstanding and an aggregate of 25,481,146 shares reserved for potential future issuance upon exercise of outstanding awards under
its 2020 Stock Incentive Plan, 2016 Long Term Incentive Plan, and its outstanding warrants. The Company may also issue up to an
additional 8,174,711 authorized shares reserved for potential issuance of future awards under its 2020 Stock Incentive Plan and
2020 Employee Stock Purchase Plan.
On
January 6, 2023, the Company held a Special Meeting of Stockholders in which the stockholders approved: (i) an amendment to the
Company’s restated certificate of incorporation to increase the number of authorized shares of our common stock by 650,000,000
(from 350,000,000 to 1,000,000,000), and (ii) an amendment to authorize the Board to amend our restated certificate of incorporation
to effect a reverse stock split of all of the outstanding shares of our common stock, at a ratio in the range of 1-for-5 to 1-for-10.
On January 19, 2023, the Board approved, and the Company filed, an amendment to the amended and restated certificate of incorporation
to increase the Company’s capitalization as described in clause (i). The Board reserves the right to adopt the proposal
described in clause (ii) at any time prior to January 6, 2024 but has no intention to effect the reverse stock split prior to
the closing of the Rights Offering and issuance of shares thereunder.
Common
Stock
Annual
Meeting. Annual meetings of our stockholders are held on the date designated in accordance with our by-laws. Written notice
must be mailed to each stockholder entitled to vote not less than ten nor more than 60 days before the date of the meeting. The
presence in person or by proxy of the holders of record of a majority of our issued and outstanding shares entitled to vote at
such meeting constitutes a quorum for the transaction of business at meetings of the stockholders. Special meetings of the stockholders
may be called for any purpose by the board of directors and shall be called by the secretary upon the written request, stating
the purpose of such meeting, of the holders of at least twenty-five percent (25%) of the shares of capital stock entitled to vote
in an election of directors. Except as may be otherwise provided by applicable law, our certificate of incorporation or our by-laws,
all elections shall be decided by a plurality, and all other questions shall be decided by a majority, of the votes cast by stockholders
entitled to vote thereon at a duly held meeting of stockholders at which a quorum is present.
Voting
Rights. Each holder of common stock is entitled to one vote for each share held of record on all matters to be voted upon
by stockholders.
Dividends.
Subject to the rights, powers and preferences of any outstanding preferred stock, and except as provided by law or in our certificate
of incorporation, dividends may be declared and paid or set aside for payment on the common stock out of legally available assets
or funds when and as declared by the board of directors.
Liquidation,
Dissolution and Winding Up. Subject to the rights, powers and preferences of any outstanding preferred stock, in the event
of our liquidation, dissolution or winding up, our net assets will be distributed pro rata to the holders of our common stock.
Other
Rights. Holders of the common stock have no right to:
| ● | convert
the stock into any other security; |
| ● | have
the stock redeemed; |
| ● | purchase
additional stock; or |
| ● | maintain
their proportionate ownership interest. |
The
common stock does not have cumulative voting rights. Holders of shares of the common stock are not required to make additional
capital contributions.
Transfer
Agent and Registrar. Computershare Trust Company, N.A. is transfer agent and registrar for the common stock.
Preferred
Stock
We
are authorized to issue “blank check” preferred stock, which may be issued in one or more series upon authorization
of our board of directors. Our board of directors is authorized to fix the designations, powers, preferences and the relative,
participating, optional or other special rights and any qualifications, limitations and restrictions of the shares of each series
of preferred stock. The authorized shares of our preferred stock are available for issuance without further action by our stockholders,
unless such action is required by applicable law or the rules of any stock exchange on which our securities may be listed. If
the approval of our stockholders is not required for the issuance of shares of our preferred stock, our board may determine not
to seek stockholder approval.
Certain
Provisions of Our Certificate of Incorporation and By-laws and Delaware Law
Board
of Directors. All of our directors are elected annually. The number of directors comprising our board of directors is fixed
from time to time by the board of directors.
Stockholder
Nomination of Directors. Our Bylaws provide that a stockholder must notify us in writing of any stockholder nomination of a
director not earlier than the 120th day and not later than the 90th day prior to the first
anniversary of the preceding year’s annual meeting; provided, that if the date of the annual meeting is advanced or delayed by
more than 30 days from such anniversary date, notice by the stockholder to be timely must be so delivered (x) not earlier than the
120th day prior to the date of such annual meeting and not later than the 90th day prior to the date
of such meeting and (y) the 10th day following the day on which public announcement of the date of such annual
meeting is first made by us.
Exclusive
forum provision. Our Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative
forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction,
the federal district court for the District of Delaware) shall be the sole and exclusive forum for the following types of proceedings:
(1) any derivative action or proceeding brought on behalf of our company, (2) any action asserting a claim of breach of a fiduciary
duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders, (3) any action asserting
a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware or as to which the General Corporation
Law of the State of Delaware confers jurisdiction on the Court of Chancery of the State of Delaware, or (4) any action asserting
a claim arising pursuant to any provision of our Certificate of Incorporation or Bylaws (in each case, as they may be amended
from time to time) or governed by the internal affairs doctrine. These choice of forum provisions will not apply to suits brought
to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction
for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction
to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary
rulings by different courts, among other considerations, our Certificate of Incorporation provides that, unless we consent in
writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest
extent permitted by law, be the sole and exclusive forum for the resolution of any claims arising under the Securities Act. While
the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek
to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to
vigorously assert the validity and enforceability of the exclusive forum provisions of our Certificate of Incorporation. This
may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance
that the provisions will be enforced by a court in those other jurisdictions.
THE
RIGHTS OFFERING
Subscription
Rights
Basic
Subscription Rights
We
will distribute to each holder of our common stock who is a record holder of our common stock on the Record Date, which is [●],
at no charge, one Subscription Right for every one share of common stock owned. The Subscription Rights will be evidenced by non-transferable
Subscription Rights certificates. Each Subscription Right will entitle the Subscription Rights holder to purchase 2.152353 shares
of common stock at the Initial Price, which shall be paid in cash, upon timely delivery of the required documents and payment
of the Subscription Price. To the extent that the Alternate Price is lower than the Initial Price, we will sell additional shares
of common stock, but we will not sell fractional shares, instead rounding down to the nearest whole number of shares a holder
would otherwise be entitled to purchase. While at this time the Company has no reason to believe the Alternate Price will decline
such that the number of shares of common stock to be offered would cause the Company to exceed the number of authorized shares
of common stock set forth in the Company’s amended certificate of incorporation, the Company has reserved the right to terminate
the Rights Offering at any time before the completion of the Rights Offering, as further disclosed herein, and may do so under those
circumstances. If Subscription Rights holders wish to exercise their Subscription Rights, they must do so prior to 5:00 p.m.,
Eastern Time, on [●], the Expiration Date for the Rights Offering, subject to extension. After the Expiration Date, the
Subscription Rights will expire and will have no value. See below “—Expiration of the Rights Offering and Extensions,
Amendments and Termination.” You are not required to exercise all of your Subscription Rights. We will issue to the
record holders who purchase shares of common stock in the Rights Offering the shares in book-entry, or uncertificated, form as
soon as practicable after the Rights Offering has expired.
Over-Subscription
Rights
Subject
to the allocation described below, each Subscription Right also grants the holder an Over-Subscription Right to purchase additional
shares of common stock that are not purchased by other Subscription Rights holders pursuant to their Basic Subscription Rights.
You are entitled to exercise your Over-Subscription Right only if you exercise your Basic Subscription Right in full.
If
you wish to exercise your Over-Subscription Right, you should indicate the number of additional shares of common stock that you
would like to purchase in the space provided on your rights certificate, as well as the number of shares that you beneficially
own without giving effect to any shares to be purchased in this Rights Offering. When you send in your rights certificate, you
must also send the full purchase price, as provided herein, for the number of additional shares of common stock that you have
requested to purchase (in addition to the payment, as provided herein, due for shares of common stock purchased through your Basic
Subscription Right). If the number of shares of common stock remaining after the exercise of all Basic Subscription Rights is
not sufficient to satisfy all requests for shares pursuant to Over-Subscription Rights, you will be allocated additional shares
in the proportion which the number of shares you purchased through the Basic Subscription Right bears to the total number of shares
that all oversubscribing stockholders purchased through the Basic Subscription Right. The subscription agent will return any excess
payments in the form in which made.
As
soon as practicable after the Expiration Date, the subscription agent will determine the number of shares of common stock that
you may purchase pursuant to the Over-Subscription Right. If you request and pay for more shares than are allocated to you, we
will refund the overpayment in the form in which made. In connection with the exercise of the Over-Subscription Right, custodian
banks, brokers, dealers and other nominee holders of Subscription Rights who act on behalf of beneficial owners will be required
to certify to us and to the subscription agent as to the aggregate number of Subscription Rights exercised, and the number of
shares of common stock requested through the Over-Subscription Right, by each beneficial owner on whose behalf the nominee holder
is acting.
Subscription
Price
The
subscription price per share of common stock will be the lesser of (i) $1.05 (the “Initial Price”) and (ii) the volume
weighted-average price of our common stock for the preceding five (5) consecutive trading days through and including the Expiration
Date (the “Alternate Price”). The Initial Price or Alternate Price, as applicable, is sometimes referred to herein
as the “Subscription Price”. The Subscription Price may present a significant discount to the recent closing trading
price of $4.23 on January 19, 2023. Following the closing of the Rights Offering, there is no assurance that the price will
remain at the current trading price, and the price may decline to the Subscription Price, or to a price lower than the Subscription
Price. For a more detailed discussion, see “Dilution” beginning on page 37. Subscribers must fund their subscriptions
pursuant to both the Basic Subscription Right and Over-Subscription Right at the Initial Price.
The
Board determined that it was in the best interests of the Company to have the Special Committee consider the Rights Offering and its
terms in light of the significant common stock ownership by the Company’s Chairman of the Board and Chief Executive Officer
and the Company’s co-Chief Executive Officer, President, and member of the Board. In determining the Subscription Price, the
Special Committee considered a number of factors, including: the likely cost of capital from other sources and general conditions of
the securities markets, the price at which our stockholders might be willing to participate in the Rights Offering, our need for
liquidity and capital, the average price for the 30-day period prior to the filing of the preliminary Proxy Statement on November
29, 2022, and the desire to provide an opportunity to our stockholders to participate in the Rights Offering on a pro rata basis.
The Special Committee determined that it was in the best interests of the Company’s stockholders to publicly announce the
Initial Price and the Alternate Price so that all stockholders had the opportunity to determine whether to buy or sell the
Company’s shares of common stock prior to the Record Date. The Company did not consider revising the Initial Price. The
Company believes this disclosure has provided its stockholders and the public with sufficient information about the Company’s
expectation to sell a significant number of shares in the Rights Offering, as described herein. The Subscription Price is not
necessarily related to our book value, net worth or any other established criteria of value and may or may not be considered the
fair value of our common stock to be offered in the Rights Offering. You should not consider the Subscription Price as an indication
of value of us or our common stock. The market price of our common stock may decline during or after the Rights Offering, including
below the Subscription Price for the common stock in the Rights Offering. You should obtain a current quote for our common stock
before exercising your Subscription Rights and make your own assessment of our business and financial condition, our prospects for
the future, and the terms of the Rights Offering.
Expiration
of the Rights Offering and Extensions, Amendments and Termination
You
may exercise your Subscription Rights at any time prior to 5:00 p.m., Eastern Time, on [●], the Expiration Date for the
Rights Offering. If you do not exercise your Subscription Rights before the Expiration Date of the Rights Offering, your Subscription
Rights will expire and will have no value. We will not be required to sell shares of common stock to you if the subscription agent
receives your rights certificate or payment, after the Expiration Date, regardless of when you sent the rights certificate and
payment.
We
may, in our sole discretion, extend the time for exercising the Subscription Rights. We may extend the Expiration Date at any
time after the Record Date. If the commencement of the Rights Offering is delayed for a period of time, the Expiration Date of
the Rights Offering may be similarly extended. We will extend the duration of the Rights Offering as required by applicable law,
and may choose to extend the duration of the Rights Offering for any reason. We may extend the Expiration Date of the Rights Offering
by giving oral or written notice to the subscription agent on or before the scheduled Expiration Date. If we elect to extend the
Expiration Date of the Rights Offering, we will issue a press release announcing such extension no later than 9:00 a.m., Eastern
Time, on the next business day after the most recently announced Expiration Date.
We
reserve the right, in our sole discretion, to amend or modify the terms of the Rights Offering. We also reserve the right to terminate
the Rights Offering at any time prior to the Expiration Date for any reason, in which event all funds received in connection with
the Rights Offering will be returned without interest or deduction to those persons who exercised their Subscription Rights as
soon as practicable.
Calculation
of Subscription Rights Exercised; Missing or Incomplete Subscription Information
If
you do not indicate the number of Subscription Rights being exercised, or do not forward full payment of the total Subscription
Price payment for the number of Subscription Rights that you indicate are being exercised, then you will be deemed to have exercised
your Subscription Rights with respect to the maximum number of whole shares of common stock that may be exercised with the aggregate
Subscription Price payment you delivered to the subscription agent. If your aggregate Subscription Price payment is greater than
the amount you owe for exercise of your Basic Subscription Right in full, you will be deemed to have exercised your Over-Subscription
Right to purchase the maximum number of shares with your over-payment.
If
an insufficient number of shares of common stock is available to fully satisfy all proper Over-Subscription Right requests, the
available shares will be distributed proportionately among Subscription Rights holders who properly exercise their Over-Subscription
Right based on the number of shares each Subscription Rights holder timely subscribed and paid for under the Basic Subscription
Right. The proration process will be repeated until all shares of common stock have been allocated or all properly made Over-Subscription
Right exercises have been fulfilled, whichever occurs earlier. Any excess subscription payments received by the subscription agent
caused by proration will be returned by the subscription agent to you by mail, without interest or penalty, as soon as practicable
after the Expiration Date of the Rights Offering. The subscription agent will return any excess payments in the form in which
it was made. Any Excess Subscription Amount resulting from the reduction of the Subscription Price from the Initial Price to the
Alternate Price will be allocated towards the purchase of additional shares of common stock (either towards your Basic Subscription
Right, if available, or towards the Over-Subscription Right if you have already exercised your Basic Subscription Right in full).
No
Fractional Shares
We
will not issue fractional shares of common stock in the Rights Offering. Subscription Rights holders will only be entitled to
purchase a whole number of shares of common stock, rounded down to the nearest whole number of shares a holder would otherwise
be entitled to purchase. Any Excess Subscription Amount resulting from the reduction of the Subscription Price from the Initial
Price to the Alternate Price will be allocated towards the purchase of additional shares of common stock (either towards your
Basic Subscription Right, if available, or towards the Over-Subscription Right if you have already exercised your Basic Subscription
Right in full). The excess amount for any fractional shares of common stock will be returned to you as soon as practicable, in
the form in which made. You will not receive interest or a deduction on any payments refunded to you under the Rights Offering.
Conditions
to the Rights Offering
We
may terminate the Rights Offering, in whole or in part, if at any time before completion of the Rights Offering there is any judgment,
order, decree, injunction, statute, law or regulation entered, enacted, amended or held to be applicable to the Rights Offering
that in the sole judgment of our board of directors would or might make the Rights Offering or its completion, whether in whole
or in part, illegal or otherwise restrict or prohibit completion of the Rights Offering. We may waive this condition and choose
to proceed with the Rights Offering even if this occurs. If we terminate the Rights Offering, in whole or in part, all affected
Subscription Rights will expire without value and all subscription payments in the form in which received by the subscription
agent will be returned in the form in which paid, without interest or deduction, as soon as practicable. See also “—Expiration
of the Rights Offering and Extensions, Amendments and Termination.”
Method
of Exercising Subscription Rights
The
exercise of Subscription Rights is irrevocable and may not be cancelled or modified. Your Subscription Rights will not be considered
exercised unless the subscription agent receives from you, your custodian bank, broker, dealer or nominee, as the case may be,
all of the required documents properly completed and executed and your full Subscription Price payment in cash, as provided herein,
prior to the Expiration Date of the Rights Offering, which is currently set to be 5:00 p.m., Eastern Time, on [●]. Subscription
Rights holders may exercise their rights as follows:
Subscription
by Registered Holders
Subscription
Rights holders who are registered holders of our common stock as of the Record Date may exercise their Subscription Right by properly
completing and executing the rights certificate together with any required signature guarantees and forwarding it, together with
payment in full, as provided herein, of the Subscription Price for each share of common stock for which they subscribe, to the
subscription agent at the address set forth under the subsection titled “—Delivery of Subscription Materials and
Payment,” on or prior to the Expiration Date.
Subscription
by DTC Participants
Banks,
trust companies, securities dealers and brokers (each, a “Nominee”) that hold shares of our common stock on the Record
Date as nominee for more than one beneficial owner may, upon proper showing to the subscription agent, exercise such beneficial
owner’s Subscription Right through DTC on the same basis as if the beneficial owners were stockholders on the Record Date.
Such Nominee may exercise the Subscription Right on behalf of the exercising beneficial owner through DTC’s PSOP Function
on the “agents subscription over PTS” procedure by (1) providing a certification as to the aggregate number of Subscription
Rights exercised by the beneficial owner on whose behalf such Nominee is acting, and (2) instructing DTC to charge the Nominee’s
applicable DTC account for the subscription payment for the new shares of common stock to facilitate the delivery of the full
subscription payment to the subscription agent. DTC must receive the subscription instructions and payment for the new shares
of common stock no later than the Expiration Date.
Subscription
by Beneficial Owners
Subscription
Rights holders who are beneficial owners of shares of our common stock as of the Record Date and whose shares are registered in
the name of a custodian bank, broker, dealer or other nominee, or would prefer to have an institution conduct the transaction
relating to the rights on their behalf, should instruct their custodian bank, broker, dealer or other nominee or institution to
exercise their rights and deliver all documents and payment, on their behalf, prior to the Expiration Date. A Subscription Rights
holder’s Subscription Rights will not be considered exercised unless the subscription agent receives from such Subscription
Rights holder or the Subscription Rights holder’s custodian bank, broker, dealer, or other nominee or institution, as the
case may be, all of the required documents and such holder’s full Subscription Price payment.
Method
of Payment
You
must timely pay the full Subscription Price, in U.S. currency, for the full number of shares of common stock at the Initial Price
you wish to acquire pursuant to the exercise of rights (including any exercise of the Over-Subscription Rights, if available)
by delivering:
| ● | a
wire transfer of immediately available funds to accounts maintained by the subscription
agent; |
| ● | a
certified check drawn against a U.S. bank payable to “Broadridge Corporate Issuer
Solutions, LLC (acting as Subscription Agent for Summit Therapeutics)”; |
| ● | a
U.S. Postal money order payable to “Broadridge Corporate Issuer Solutions, LLC
(acting as Subscription Agent for Summit Therapeutics)”; |
| ● | some
combination thereof; or |
| ● | other
method otherwise acceptable to the Company. |
Rights
certificates received after the Expiration Date of the Rights Offering will not be honored, and we will return your payment to
you in the form received as soon as practicable, without interest or deduction. The subscription agent will not accept uncertified
personal checks, bank drafts or cashier’s checks as a means of payment.
The
subscription agent will be deemed to receive payment upon:
| ● | receipt
of collected funds wired in the subscription agent’s account; |
| ● | receipt
by the subscription agent of any certified check drawn upon a U.S. bank; |
| ● | receipt
by the subscription agent of any U.S. Postal money order; or |
| ● | other
method otherwise acceptable to the Company. |
If,
on the Expiration Date, the Alternate Price is lower than the Initial Price, any Excess Subscription Amounts paid by a subscriber
will be allocated towards the purchase of additional shares of common stock.
Instructions
for Completing Your Subscription Rights Certificate
You
should read the instruction letter accompanying the rights certificate carefully and strictly follow it. DO NOT SEND RIGHTS
CERTIFICATES OR PAYMENTS TO THE COMPANY. We will not consider your subscription received until the subscription agent has
received delivery of a properly completed and duly executed rights certificate and payment of the full subscription amount as
set forth herein. The risk of delivery of all documents and payments is on you or your nominee, not us or the subscription agent.
The
method of delivery of rights certificates and payment of the subscription amount to the subscription agent will be at the risk
of the holders of rights, but, if sent by mail, we recommend that you send those certificates and payments by overnight courier
or by registered mail, properly insured, with return receipt requested, and that a sufficient number of days be allowed to ensure
delivery to the subscription agent and clearance of payment before the expiration of the subscription period.
Unless
a rights certificate provides that the shares of common stock are to be delivered to the record holder of such rights or such
certificate is submitted for the account of a bank or a broker, signatures on such rights certificate must be guaranteed by an
“Eligible Guarantor Institution,” as such term is defined in Rule 17Ad-15 of the Securities Exchange Act of 1934 (an
“Eligible Institution”), subject to any standards and procedures adopted by the subscription agent. See “—Medallion
Guarantee May Be Required.”
Medallion
Guarantee May Be Required
If
you completed any part of the Subscription Rights certificate to provide that the common stock purchased pursuant to your exercise
of Subscription Rights were to be (x) issued in a name other than that of the registered holder, or (y) issued to an address other
than that shown on the front of the Subscription Rights certificate, your signature on each Subscription Rights certificate must
be guaranteed by an Eligible Institution, such as a member firm of a registered national securities exchange or a member of the
Financial Industry Regulatory Authority, Inc., or a commercial bank or trust company having an office or correspondent in the
United States, or by a member of a Stock Transfer Association approved medallion program such as STAMP, SEMP or MSP subject to
standards and procedures adopted by the subscription agent.
Subscription
and Information Agent
The
subscription agent and information agent for this Rights Offering is Broadridge Corporate Issuer Solutions, LLC. We will pay all
fees and expenses of Broadridge related to the Rights Offering and have also agreed to indemnify Broadridge from certain liabilities
that it may incur in connection with the Rights Offering. Broadridge can be contacted at the following address and telephone number:
Broadridge
Corporate Issuer Solutions, LLC
Attn: BCIS Re-Organization Dept.
P.O. Box 1317
Brentwood, NY 11717-0718
Toll Free: 1-855-793-5068
Delivery
of Subscription Materials and Payment
You
should deliver your Subscription Rights certificate and payment of the Subscription Price, as provided herein, or, if applicable,
nominee holder certifications, to the subscription agent by one of the methods described below:
By
Mail:
Broadridge
Corporate Issuer Solutions, LLC
Attn:
BCIS Re-Organization Dept.
P.O.
Box 1317
Brentwood,
NY 11717-0718
|
By
Overnight Delivery:
Broadridge
Corporate Issuer Solutions, LLC
Attn:
BCIS IWS
51
Mercedes Way
Edgewood,
NY 11717
|
Your
delivery to an address or by any method other than as set forth above will not constitute valid delivery and we may not honor
the exercise of your Subscription Rights.
You
should direct any questions or requests for assistance concerning the method of subscribing for shares of common stock or for
additional copies of this prospectus to the information agent.
Funding
Arrangements; Return of Funds
Broadridge
Corporate Issuer Solutions, LLC, the subscription agent, will hold funds received in payment for shares of common stock in a segregated
account pending completion of the Rights Offering. The subscription agent will hold this money until the Rights Offering is completed
or is withdrawn or terminated. If the Rights Offering is canceled for any reason, all subscription payments received by the subscription
agent will be returned to subscribers, without interest or penalty, as soon as practicable.
Guaranteed
Delivery
There
is no guaranteed delivery period in connection with this Rights Offering, so you must ensure that you properly complete all required
steps prior to 5:00 p.m., Eastern Time, on [●], unless we decide to extend the Expiration Date until some later time or
terminate it earlier.
Notice
to Beneficial Holders
If
you are a broker, a trustee or a depositary for securities who holds shares of our common stock for the account of others as of
the Record Date, you should notify the respective beneficial owners of such shares of the Rights Offering as soon as possible
to find out their intentions with respect to exercising their Subscription Rights. You should obtain instructions from the beneficial
owners with respect to their Subscription Rights, as set forth in the instructions we have provided to you for your distribution
to beneficial owners. If a beneficial owner so instructs, you should complete the appropriate Subscription Rights certificates
and submit them to the subscription agent with the proper payment. If you hold shares of our common stock for the account(s) of
more than one beneficial owner, you may exercise the number of Subscription Rights to which all such beneficial owners in the
aggregate otherwise would have been entitled had they been direct record holders of our common stock on the Record Date, provided
that you, as a nominee record holder, make a proper showing to the subscription agent by submitting the form entitled “Nominee
Holder Certification” substantially in the form accompanying this prospectus. If you did not receive this form, you should
contact the subscription agent to request a copy.
Beneficial
Owners
If
you are a beneficial owner of shares of our common stock or will receive Subscription Rights through a custodian bank, broker,
dealer or other nominee, we will ask your custodian bank, broker, dealer or other nominee to notify you of the Rights Offering.
If you wish to exercise your Subscription Rights, you will need to have your custodian bank, broker, dealer or other nominee act
for you. If you hold shares of our common stock directly under your name in stock certificate(s) or in book-entry, or uncertificated,
form, but would prefer to have your custodian bank, broker, dealer or other nominee act for you, you should contact your nominee
and request it to effect the transactions for you. Your nominee may establish a deadline prior to the Expiration Date by which
you must provide it with your instructions to exercise your Subscription Rights and payment for your shares.
To
indicate your decision with respect to your Subscription Rights, you should complete and return to your custodian bank, broker,
dealer or other nominee the form entitled “Beneficial Owners Election Form” substantially in the form accompanying
this prospectus. You should receive the “Beneficial Owners Election Form” from your custodian bank, broker, dealer
or other nominee with the other Rights Offering materials. If you wish to obtain a separate Subscription Rights certificate, you
should contact the nominee as soon as possible and request that a separate Subscription Rights certificate be issued to you. You
should contact your custodian bank, broker, dealer or other nominee if you do not receive this form but you believe you are entitled
to participate in the Rights Offering. We are not responsible if you do not receive this form from your custodian bank, broker,
dealer or nominee or if you receive it without sufficient time to respond.
No
Revocation or Change
Once
you submit the form of rights certificate to exercise any Subscription Rights, you may not revoke or change your exercise or request
a refund of monies paid. All exercises of rights are irrevocable, even if you subsequently learn information about us that you
consider to be unfavorable. You should not exercise your Subscription Rights unless you are certain that you wish to purchase
additional shares of common stock at the Initial Price.
Non-Transferability
of the Rights
The
Subscription Rights granted to you are non-transferable and, therefore, may not be assigned, gifted, purchased, sold or otherwise
transferred to anyone else. Notwithstanding the foregoing, you may transfer your Subscription Rights as required by operation
of law; for example, a transfer of rights to the estate of the recipient upon the death of the recipient would be permitted. If
the rights are transferred as permitted, evidence satisfactory to us that the transfer was proper must be received by us prior
to the Expiration Date.
Issuance
of Common Stock
All
shares of our common stock that you purchase in the Rights Offering will be issued in book-entry, or uncertificated, form, meaning
that you will receive a direct registration (DRS) account statement from our transfer agent reflecting ownership of these securities
if you are a holder of record of shares or warrants. If you hold your shares of common stock in the name of a custodian bank,
broker, dealer, or other nominee, DTC will credit your account with your nominee with the securities you purchased in the Rights
Offering. Subject to state securities laws and regulations, we have the discretion to delay distribution of any securities you
may have elected to purchase by exercise of your Subscription Rights in order to comply with state securities laws.
Validity
of Subscriptions
We
will resolve all questions regarding the validity and form of the exercise of your Subscription Rights, including time of receipt
and eligibility to participate in the Rights Offering. Our determination will be final and binding. Once made, subscriptions and
directions are irrevocable, and we will not accept any alternative, conditional or contingent subscriptions or directions. We
reserve the absolute right to reject any subscriptions or directions not properly submitted or the acceptance of which would be
unlawful. You must resolve any irregularities in connection with your subscriptions before the subscription period expires, unless
waived by us in our sole discretion. Neither the subscription agent nor we shall be under any duty to notify you or your representative
of defects in your subscriptions. A subscription will be considered accepted, subject to our right to cancel the Rights Offering,
only when a properly completed and duly executed Subscription Rights certificate and any other required documents and payment
of the full subscription amount have been received by the subscription agent and any defects or irregularities therein waived
by us. Our interpretations of the terms and conditions of the Rights Offering will be final and binding.
Rights
of Subscribers
You
will have no rights as a holder of the shares of our common stock you purchase in the Rights Offering until shares are issued
in book-entry form or your account at your broker, dealer, bank or other nominee is credited with the shares of our common stock
purchased in the Rights Offering. You will have no right to revoke your subscriptions after you deliver your completed rights
certificate, subscription payment, as provided herein, and any other required documents to the subscription agent.
Foreign
Stockholders and Stockholders with Army Post Office or Fleet Post Office Addresses
The
subscription agent will not mail rights certificates to you if you are a registered stockholder whose address is outside the United
States or if you have an Army Post Office or a Fleet Post Office address. Instead, we will have the subscription agent hold the
Subscription Rights certificates for your account. To exercise your Subscription Rights, you must notify the subscription agent
prior to 11:00 a.m., Eastern Time, at least three (3) business days prior to the Expiration Date and establish to the satisfaction
of the subscription agent that it is permitted to exercise your Subscription Rights under applicable law. If you do not follow
these procedures by such time, your Subscription Rights will expire and will have no value. If you hold your shares in the name
of a custodian bank, broker, dealer or other nominee, you should follow the instructions you receive from it, as described above.
No
Board of Directors Recommendation
An
investment in the Company’s common stock must be made according to your evaluation of your own best interests and after
considering all of the information herein, including the section titled “Risk Factors” beginning on page 23
of this prospectus. Neither we nor our board of directors are making any recommendation regarding whether you should exercise
your Subscription Rights.
Purchase
Commitments
Robert
W. Duggan, our Executive Chairman, Chief Executive Officer, and the beneficial owner of approximately 78.1% of our outstanding
common stock prior to this Rights Offering, and Dr. Mahkam Zanganeh, our co-Chief Executive officer, President, a member of our
Board of Directors, and the beneficial owner of approximately 6.0% of our issued and outstanding common stock prior to this Rights
Offering, have each indicated that they intend to participate in the Rights Offering and
subscribe for at least the full amount of their Basic Subscription Rights, but have not made any formal binding commitment to
participate.
Shares
of Common Stock Outstanding After the Rights Offering
The
number of shares of our common stock that will be outstanding after the Rights Offering will depend on the number of shares of
common stock that are purchased in the Rights Offering. Assuming no additional shares of common stock are issued by us prior to
consummation of the Rights Offering and assuming all offered shares of common stock are sold in the Rights Offering at the Initial
Price, we will issue approximately 476,190,476 shares of common stock. In that case, we will have approximately 697,432,201 shares
of common stock outstanding after the Rights Offering. This would represent an increase of approximately 215% in the number of
outstanding shares of common stock. To the extent that the Alternate Price is lower than the Initial Price, we will sell additional
shares of common stock in the Rights Offering, and the number of shares of common stock outstanding after the Rights Offering
will accordingly be higher.
Fees
and Expenses
Neither
we, nor the subscription agent, will charge a brokerage commission or a fee to Subscription Rights holders for exercising their
rights. However, if you exercise your Subscription Rights through a custodian bank, broker, dealer or nominee, you will be responsible
for any fees charged by your custodian bank, broker, dealer or nominee.
Questions
About Exercising Subscription Rights
If
you have any questions or require assistance regarding the method of exercising your Subscription Rights or requests for additional
copies of this document or any document mentioned herein, you should contact the subscription agent at the address and telephone
number set forth above under “— Delivery of Subscription Materials and Payment.”
No
“Going Private” Transaction
The
Rights Offering is not a transaction or series of transactions which has either a reasonable likelihood or a purpose of producing
a “going private effect” as specified in Rule 13e-3 of the Exchange Act. Given the structure of the Rights Offering,
as described in this prospectus, the Company will continue to be registered pursuant to Section 12 of the Exchange Act and intends
to remain listed on the Nasdaq Global Market following completion of the Rights Offering.
Other
Matters
The
Company is not making the Rights Offering in any state or other jurisdiction in which it is unlawful to do so, nor is the Company
distributing or accepting any offers to purchase any of our securities from Subscription Rights holders who are residents of those
states or of other jurisdictions or who are otherwise prohibited by federal or state laws or regulations to accept or exercise
the Subscription Rights. The Company may delay the commencement of the Rights Offering in those states or other jurisdictions,
or change the terms of the Rights Offering, in whole or in part, in order to comply with the securities law or other legal requirements
of those states or other jurisdictions. Subject to state securities laws and regulations, the Company also has the discretion
to delay allocation and distribution of any securities you may elect to purchase by exercise of your Subscription Rights in order
to comply with state securities laws. The Company may decline to make modifications to the terms of the Rights Offering requested
by those states or other jurisdictions, in which case, if you are a resident in one of those states or jurisdictions or if you
are otherwise prohibited by federal or state laws or regulations from accepting or exercising the Subscription Rights you will
not be eligible to participate in the Rights Offering.
MATERIAL
U.S. FEDERAL INCOME TAX CONSEQUENCES
The
following summary does not purport to be a complete analysis of all of the potential U.S. federal income tax considerations, and
does not address any tax consequences arising under any state, local or non-U.S. tax laws or any other U.S. federal tax laws,
including the U.S. federal estate or gift tax laws. This discussion applies only to holders who are U.S. persons (as defined below)
and does not address all aspects of U.S. federal income taxation that may be relevant to holders in light of their particular
circumstances or to holders who may be subject to special tax treatment under the Code, including, without limitation, holders
who are dealers in securities or non-U.S. currency, non-U.S. persons, certain former citizens or long-term residents of the United
States, insurance companies, tax-exempt organizations, banks, financial institutions or broker-dealers, holders who hold our common
stock as part of a hedge, straddle, conversion or other risk reduction transaction, or holders who acquired our common stock pursuant
to the exercise of compensatory stock options or otherwise as compensation.
This
summary is of a general nature only and is not intended to constitute a complete analysis of all tax consequences relating to
the receipt, exercise and expiration of the Subscription Rights, and the ownership and disposition of our common stock. It is
not intended to constitute, and should not be construed to constitute, legal or tax advice to any particular holder. This discussion
neither binds nor precludes the Internal Revenue Service (“IRS”) from adopting a position contrary to, or otherwise
challenging, the positions addressed in this prospectus, and we cannot assure you that such a contrary position will not be asserted
successfully by the IRS or adopted by a court if the position or matter was litigated. We have not sought, and will not seek,
either (i) a ruling from the IRS or (ii) an opinion from legal counsel, in either instance regarding the tax considerations
discussed herein. Holders should consult their own tax advisors as to the tax consequences in their particular circumstances.
For
purposes of this discussion, a “U.S. person” means a beneficial owner of Subscription Rights that is:
|
● |
An individual who is a citizen or resident of
the United States; |
|
|
|
|
● |
A corporation (or entity treated as a corporation
for U.S. federal income tax purposes) created or organized, or treated as created or organized, in or under the laws of the
United States, any state thereof or the District of Columbia; |
|
|
|
|
● |
An estate whose income is subject to U.S. federal
income tax regardless of its source; or |
|
|
|
|
● |
A
trust (i) if a U.S. court can exercise primary supervision over the trust’s administration and one or more
U.S. persons are authorized to control all substantial decisions of the trust, or (ii) that has a valid election
in effect under applicable Treasury Regulations promulgated under the Code (“Treasury Regulations”) to be
treated as a U.S. person.
|
If
a partnership (including any entity treated as a partnership for U.S. federal income tax purposes) receives the Subscription Rights
or holds the stock received upon exercise of the Subscription Right, the tax treatment of a partner in such partnership generally
will depend upon the status of the partner and the activities of the partnership. Such a partner and the partnership are urged
to consult their own tax advisors as to the U.S. federal income tax consequences of receiving the Subscription Rights and exercising
(or allowing to expire) the Subscription Rights.
This
discussion does not describe all of the tax considerations which may be relevant to a particular holder’s ownership of the
shares of common stock received upon exercise of the Basic Subscription Rights or the Over-Subscription Rights.
EACH
HOLDER OF SHARES OF OUR COMMON STOCK IS STRONGLY URGED TO CONSULT SUCH HOLDER’S OWN TAX ADVISORS REGARDING THE SPECIFIC
FEDERAL, STATE, LOCAL AND NON-U.S. INCOME AND OTHER TAX CONSIDERATIONS OF THE RECEIPT AND EXERCISE OF THE SUBSCRIPTION RIGHTS,
AND THE OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK.
U.S.
Federal Income Tax Considerations Applicable to the Receipt of Subscription Rights
Receipt
of Subscription Rights
Under
section 61(a)(3) of the Code, gross income includes “gains derived from dealings in property.” Under section 301 of
the Code, “a distribution of property… made by a corporation to its stockholder with respect to its stock”
is taxable as gross income to the extent that the distribution is made out of the corporation’s current or accumulated earnings
and profits. If at the time of the distribution the corporation does not have current or accumulated earnings and profits, then
the amount of the distribution is applied first as a reduction in the stockholder’s basis in its stock; the amount of any
distribution in excess of the stockholder’s basis is treated as a capital gain from the sale or exchange of property.
Code
section 305(a), however, provides that gross income does not include “the amount of any distribution of the stock of a corporation
made by such corporation to its stockholders with respect to its stock.” For purposes of Code section 305, “stock”
is defined in Code section 305(d)(1) to include rights to acquire such stock.
The
general rule set forth in Code section 305(a) regarding nonrecognition is subject to certain exceptions, including if receipt
by a holder of Subscription Rights is part of a “disproportionate distribution” as set forth in Code section 305(b)(2).
A “disproportionate distribution” is a distribution or a series of distributions, including deemed distributions,
that has the effect of the receipt of cash or other property by some holders and an increase in the proportionate interest of
other holders in our assets or earnings and profits. During the last 36 months, we have made a distribution of Subscription Rights
to holders of our common stock. Our common stock was then and is now our sole outstanding class of stock, and we have no current
intention of issuing another class of stock or convertible debt. The fact that we have made a prior distribution of Subscription
Rights within the last 36 months means that the 36-month safe harbor rule set forth in the Treasury Regulations will not apply
and, therefore, the distribution of Subscription Rights will not be presumed to not result in the receipt of cash or property
by some stockholders and an increase in the proportionate interest of other stockholders. We also have outstanding options (issued
as equity awards) which could cause, under certain circumstances that cannot be predicted currently, the receipt of Subscription
Rights pursuant to this Rights Offering to be part of a disproportionate distribution. The Company believes that the distribution
of Subscription Rights in this Rights Offering is not likely to constitute an increase in the proportionate interest of some stockholders
in the assets or earnings and profits of the Company for purposes of Code section 305(b)(2) based on the fact that all of our
stockholders will receive rights in the Rights Offering based upon their respective ownership of our common stock. The Company
also intends to take the position that the outstanding options (issued as equity awards) and their potential exercise do not cause
the Subscription Rights issued pursuant to this Rights Offering to be part of a disproportionate distribution, but there can be
no assurances in this regard.
Our
position regarding the tax-free treatment of the receipt of Subscription Rights in this Rights Offering is not binding on the
IRS or the courts, and there can be no assurance that the IRS or any applicable court would agree. If this position were finally
determined to be incorrect, whether on the basis that the issuance of the subscriptions rights is a “disproportionate distribution”
or otherwise, the fair market value of the Subscription Rights would be taxable to holders of our common stock as a dividend on
the date of the distribution to the extent of the holder’s pro rata share of our current and accumulated earnings and profits,
if any, with any excess being treated as a return of capital to the extent of the holder’s basis in shares of our common
stock and thereafter as capital gain. Although no assurance can be given, it is anticipated that we will not have current and
accumulated earnings and profits through the end of 2022.
The
following discussion assumes that the receipt by a holder of Subscription Rights with respect to such holder’s common stock
pursuant to this Rights Offering is non-taxable for U.S. federal income tax purposes.
Tax
Basis in the Subscription Rights
A
holder’s tax basis in its Subscription Rights will depend on the relative fair market value of the Subscription Rights received
by such holder and the common stock owned by such holder at the time the Subscription Rights are distributed. If either (i) the
fair market value of the Subscription Rights on the date such Subscription Rights are distributed is equal to at least 15% of
the fair market value on such date of the common stock with respect to which the Subscription Rights are received or (ii) the
holder elects, in its U.S. federal income tax return for the taxable year in which the Subscription Rights are received, to allocate
part of its tax basis in such common stock to the Subscription Rights, then upon exercise of the Subscription Rights (and upon
exercise, between the old stock and the stock received upon the exercise of the rights), the holder’s tax basis in the common
stock will be allocated between the common stock and the Subscription Rights in proportion to their respective fair market values
on the date the Subscription Rights are distributed. If the Subscription Rights received by a holder have a fair market value
that is less than 15% of the fair market value of the common stock owned by such holder at the time the Subscription Rights are
distributed, the holder’s tax basis in its Subscription Rights will be zero unless the holder elects to allocate its adjusted
tax basis in the common stock owned by such holder in the manner described in the previous sentence. The fair market value of
the Subscription Rights on the date the Subscription Rights are received is uncertain, and we have not obtained, and do not intend
to obtain, an appraisal of the fair market value of the Subscription Rights as of that date. Therefore, you should consult with
your tax advisor to determine the proper allocation of basis between the Subscription Rights and the shares of common stock with
respect to which the Subscription Rights are received.
Expiration
of Subscription Rights
A
holder that allows the Subscription Rights received in the Rights Offering to expire will not recognize any gain or loss, and
the tax basis in the common stock owned by such holder with respect to which such Subscription Rights were distributed will be
equal to the tax basis in such common stock immediately before the receipt of the Subscription Rights in the Rights Offering.
Exercise
of Subscription Rights and Holding Period
A
holder will not recognize any gain or loss upon the exercise of the Subscription Rights received in the Rights Offering. The tax
basis in the common stock acquired through exercise of the Subscription Rights will equal the sum of the Subscription Price for
the common stock and the holder’s tax basis, if any, allocated to the rights as described above. The holding period for
the common stock acquired through exercise of the Subscription Rights will begin on the date the Subscription Rights are exercised.
Holders who exercise Subscription Rights after disposing of all of the shares of the common stock owned by such holder should
consult with their own tax advisor regarding the allocation of tax basis.
U.S.
Federal Income Tax Considerations Applicable to Our Common Shares
Distributions
Distributions
with respect to shares of our common stock acquired upon exercise of Subscription Rights will be taxable as dividend income when
actually or constructively received to the extent of our current or accumulated earnings and profits as determined for U.S. federal
income tax purposes. The excess will generally be treated first as a return of capital to the extent of a holder’s adjusted
tax basis in its shares of our common stock, and, thereafter, as capital gain.
Dividend
income received by certain non-corporate holders with respect to shares of our common stock generally will be “qualified
dividends” subject to preferential rates for U.S. federal income tax purposes, provided that the holder meets applicable
holding period and other requirements. Subject to similar exceptions for short-term and hedged positions, dividend income on our
shares of common stock paid to holders that are domestic corporations generally will potentially qualify for the dividends-received
deduction.
Dispositions
A
holder which sells or otherwise disposes of shares of common stock acquired upon exercise of Subscription Rights in a taxable
transaction generally will recognize capital gain or loss equal to the difference between the amount realized and such holder’s
adjusted tax basis in the shares. Such capital gain or loss will be long-term capital gain or loss if a holder’s holding
period for such shares is more than one year at the time of disposition. Long-term capital gain of a non-corporate holder is generally
taxed at preferential U.S. income tax rates. The deductibility of capital losses is subject to limitations.
Information
Reporting and Backup Withholding
U.S.
backup withholding (currently at a rate of 24%) is imposed upon certain distributions (or deemed distributions) to persons who
fail (or are unable) to furnish the information required pursuant to U.S. information reporting requirements. Distributions (or
deemed distributions or similar transactions) to a holder will generally be exempt from backup withholding, provided the holder
meets applicable certification requirements, including (i) providing us with such holder’s U.S. taxpayer identification
number (e.g., an individual’s social security number or individual taxpayer identification number, or an entity’s
employer identification number, each a “TIN”) or (ii) otherwise establishing an exemption (e.g., an
exemption from backup withholding as a corporate payee), in each instance on a properly completed IRS Form W-9, certifying under
penalties of perjury that, among others, such TIN or exemption is correct, together with such other certifications as may be required
by law.
Backup
withholding does not represent an additional tax. Any amounts withheld from a payment to a holder under the backup withholding
rules will generally be allowed as a credit against such holder’s U.S. federal income tax liability, and may entitle such
holder to a refund, provided the required information and returns are timely furnished by such holder to the IRS.
AS
INDICATED ABOVE, THE FOREGOING DISCUSSION IS FOR GENERAL INFORMATION PURPOSES ONLY AND SHOULD NOT BE VIEWED AS COMPLETE OR COMPREHENSIVE
TAX ADVICE. HOLDERS RECEIVING A DISTRIBUTION OF STOCK RIGHTS CONTEMPLATED IN THIS RIGHTS OFFERING AND HOLDERS CONSIDERING THE
PURCHASE OF OUR COMMON STOCK BY EXERCISING SUCH STOCK RIGHTS ARE URGED TO CONSULT THEIR OWN TAX ADVISORS REGARDING THE APPLICATION
OF THE U.S. FEDERAL TAX LAWS TO THEIR PARTICULAR SITUATIONS AND THE APPLICABILITY AND EFFECT OF STATE, LOCAL AND NON-U.S. LAWS
TO THEM.
PLAN
OF DISTRIBUTION
We
are distributing rights certificates and copies of this prospectus to those persons who were holders of our common stock on [●],
the Record Date for the Rights Offering, following the effective date of the registration statement of which this prospectus forms
a part. We have not employed any brokers, dealers or underwriters in connection with the solicitation or exercise of rights in
the Rights Offering and no commissions, fees or discounts will be paid in connection with the Rights Offering. While certain of
our directors, officers and other employees may solicit responses from you, those directors, officers and other employees will
not receive any commissions or compensation for their services other than their normal compensation, and will not register with
the SEC as brokers in reliance on certain safe harbor provisions contained in Rule 3a4-1 under the Exchange Act.
Delivery
of Subscription Rights
As
soon as practicable after the Record Date for the Rights Offering, we will distribute the rights, rights certificates and copies
of this prospectus to individuals who owned shares of common stock on 4:00 p.m., Eastern Time, on [●]. If your shares are
held in the name of a custodian bank, broker, dealer or other nominee, then you should send your subscription documents and subscription
payment to that record holder. If you are the record holder, then you should send your subscription documents, rights certificate,
and subscription payment to the subscription agent, Broadridge Corporate Issuer Solutions, LLC, at the following address. If sent
by mail, we recommend that you send documents and payments by registered mail, properly insured, with return receipt requested,
and that a sufficient number of days be allowed to ensure delivery to the subscription agent. Do not send or deliver these materials
to the Company.
By
Mail:
Broadridge
Corporate Issuer Solutions, LLC
Attn:
BCIS Re-Organization Dept.
P.O.
Box 1317
Brentwood,
NY 11717-0718
|
By
Overnight Delivery:
Broadridge
Corporate Issuer Solutions, LLC.
Attn:
BCIS IWS
51
Mercedes Way
Edgewood,
NY 11717
|
In
the event that the Rights Offering is not fully subscribed, holders of rights who exercise all of their rights pursuant to their
Basic Subscription Right will have the opportunity to subscribe for additional shares of common stock pursuant to the Over-Subscription
Right. See further the section titled “The Rights Offering” beginning on page 40.
We
have not agreed to enter into any standby or other arrangement to purchase or sell any rights or any of our securities. Robert
W. Duggan, our Executive Chairman, Chief Executive Officer, and the beneficial owner of approximately 78.1% of our outstanding
common stock prior to this Rights Offering, and Dr. Mahkam Zanganeh, our co-Chief Executive Officer, President, a member of our
Board of Directors, and the beneficial owner of approximately 6.0% of our issued and outstanding common stock prior to this Rights
Offering, have each indicated that they intend to participate in the Rights Offering and
subscribe for at least the full amount of their Basic Subscription Rights, but have not made any formal binding commitment to
participate.
We
have not entered into any agreements regarding stabilization activities with respect to our securities. If you have any questions,
you should contact the information agent at Broadridge Corporate Issuer Solutions, LLC, Attn: BCIS Re-Reorganization Dept., P.O.
Box 1317, Brentwood, NY 11717-0718, by telephone at 1-855-793-5068 or by email at shareholder@broadridge.com. We have agreed to
pay Broadridge Corporate Issuer Solutions, LLC a fee plus certain expenses, which we estimate will total approximately $50,000.
We estimate that our total expenses in connection with the Rights Offering will be approximately $500,000.
Other
than as described herein, we do not know of any existing agreements between any stockholder, broker, dealer, underwriter or agent
relating to the sale or distribution of the shares of common stock.
LEGAL
MATTERS
Baker & Hostetler, LLP will pass upon the validity of any securities we offer by this prospectus.
EXPERTS
The
financial statements as of and for the year ended December 31, 2021 incorporated by reference in this prospectus by reference
to the Annual Report on Form 10-K/A for the year ended December 31, 2021 have been so incorporated in reliance on the report (which
contains an emphasis of matter paragraph related to the Company’s requirement for additional financing to fund future operations
and management’s plans as described in Note 3 to the consolidated financial statements) of PricewaterhouseCoopers LLP (a
Delaware limited liability partnership), an independent registered public accounting firm, given on the authority of said firm
as experts in auditing and accounting.
The
financial statements as of and for the year ended December 31, 2020 incorporated by reference in this prospectus by reference
to the Annual Report on Form 10-K/A for the year ended December 31, 2021 have been so incorporated in reliance on the report of
PricewaterhouseCoopers LLP (a United Kingdom entity), an independent registered public accounting firm, given on the authority
of said firm as experts in auditing and accounting.
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
The
SEC allows us to “incorporate by reference” information into this prospectus. This means that we can disclose important
information about us and our financial condition to you by referring you to other documents filed separately with the SEC. The
information incorporated by reference is considered to be a part of this prospectus, except any information that is superseded
by information that is included in a document subsequently filed with the SEC.
This
prospectus incorporates by reference the documents listed below that we have previously filed with the SEC and any future filings
we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), from the date of this prospectus until the termination of an offering of securities, except that we are not incorporating
by reference any information furnished (and not filed) with the SEC, including any information furnished pursuant to Items 2.02
or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K:
| ● | Our Annual Report on Form 10-K for the fiscal year ended December
31, 2021, as filed on March 17, 2022 (except for the consolidated financial statements on pages 91 to 127); |
| ● | The
Annual Report on Form 10-K/A for the fiscal year ended December 31, 2021, as filed on
December 22, 2022; |
| ● | Our Current Reports on Form 8-K filed on January
12, 2022, January
25, 2022, February
9, 2022, March 11,
2022, June 1, 2022,
June 22, 2022, June
22, 2022, July 14,
2022; July 18, 2022,
July 26, 2022, July
29, 2022, August
9, 2022, August 16,
2022, October 3,
2022, October 4,
2022, November 17,
2022, December 6,
2022, December 21,
2022, December 27,
2022, and January
9, 2023 (except for information contained therein which is furnished rather than filed) and January 20, 2023; |
| ● | Our Definitive Proxy Statements on Schedule 14A filed on April
29, 2022 (only the information specifically incorporated by reference into our Annual Report on Form 10-K for the fiscal year
ended December 31, 2021) and December
13, 2022 (the “Proxy Statement”); |
| ● | The description of the securities contained in our Current Report on Form 8-K dated September
18, 2020, including any amendment or report filed for the purpose of updating such description. |
Any
statement contained in a document all or a portion of which is incorporated or deemed to be incorporated by reference herein will
be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document
which also is or is deemed to be incorporated by reference
herein modifies or supersedes such statement. Any statement so modified will not be deemed to constitute a part hereof, except
as so modified, and any statement so superseded will not be deemed to constitute a part hereof.
A
copy of any document incorporated by reference in this prospectus may be obtained at no cost by writing or telephoning us at the
following address and telephone number:
Summit
Therapeutics Inc.
2882
Sand Hill Road, Suite 106
Menlo
Park, CA 94025
Attention:
Investor Relations
(617)-514-7149
We
maintain a website at www.smmttx.com. Information about us, including our reports filed with the SEC, is available through
that site. Such reports are accessible at no charge through our website and are made available as soon as reasonably practicable
after such material is filed with or furnished to the SEC. Our website and the information contained on that website, or connected
to that website, are not incorporated by reference in this prospectus.
You
may read and copy any materials we file with the SEC at the SEC’s website mentioned under the heading “Where You
Can Find More Information.” The information on the SEC’s website is not incorporated by reference in this prospectus.
WHERE
YOU CAN FIND MORE INFORMATION
We
file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available
to the public over the Internet at the SEC's website at www.sec.gov. Copies of certain information filed by us with the SEC are
also available on our website at www.smmttx.com. The information contained in, or accessible through, our website, however,
should not be considered a part of this prospectus.
This
prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information
included in the registration statement and the amendments, exhibits and schedules thereto, in accordance with SEC rules and regulations.
You should review the information and exhibits in the registration statement for further information on us and our consolidated
subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed as an exhibit
to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by
reference to these filings. You should review the complete document to evaluate these statements. You can obtain a copy of the
registration statement from the SEC at the address listed above or from the SEC’s website.
PART
II — INFORMATION NOT REQUIRED IN THE PROSPECTUS
Item
13. Other Expenses of Issuance and Distribution.
The
following table sets forth all expenses, payable by the registrant in connection with the sale of its common stock being registered.
All the amounts shown are estimates except the SEC registration fee.
|
| Amount
to be Paid | |
SEC Registration Fee | |
$ | 55,100 | |
Subscription and Information Agent Expenses | |
$ | 16,000 | |
Printing Expenses | |
$ | 8,250 | |
Accounting Fees and Expenses | |
$ | 125,000 | |
Legal Fees and Expenses | |
$ | 200,000 | |
Miscellaneous | |
$ | 95,650 | |
Total | |
$ | 500,000 | |
We
are paying all expenses of the Rights Offering listed above. No portion of these expenses will be borne by our stockholders.
Item
14. Indemnification of Directors and Officers.
Section
145(a) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party to or is threatened
to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative
or investigative (other than an action by or in the right of the corporation), because he or she is or was a director, officer,
employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such
action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed
to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe
his or her conduct was unlawful.
Section
145(b) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to
be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment
in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the
request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust
or other enterprise, against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection
with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed
to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect to
any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the
extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view
of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the Court
of Chancery or other adjudicating court shall deem proper.
Section
145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is
or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a
director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any
liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as
such, whether or not the corporation would have the power to indemnify the person against such liability under Section 145 of
the DGCL.
The
registrant’s Certificate of Incorporation provides that the registrant will indemnify each person who was or is a party
or threatened to be made a party to or is involved in any threatened, pending or completed action, suit or proceeding, whether
civil, criminal, administrative or investigative (other than an action by or in the right of the registrant) by reason of the
fact that he or she is or was a director or officer of the registrant, or is or was serving at the registrant’s request
as a director or officer of another corporation, partnership, joint venture, trust or other enterprise to the fullest extent permitted
by the DGCL. The registrant’s Certificate of Incorporation provides that any reasonable, documented, out-pocket expenses
must be advanced to these indemnitees under certain circumstances.
The
indemnification provisions contained in the registrant’s Certificate of Incorporation are not exclusive. In addition, the
registrant has entered into indemnification agreements with each of its directors and executive officers. Each indemnification
agreement provides that the registrant will indemnify the director or executive officer to the fullest extent permitted by law
for claims arising in his or her capacity as a director or executive officer, provided that he or she acted in good faith and
in a manner that he or she reasonably believed to be in, or not opposed to, the registrant’s best interests and, with respect
to any criminal proceeding, had no reasonable cause to believe that his or her conduct was unlawful. In the event that the registrant
does not assume the defense of a claim against a director or executive officer, the registrant is required to advance his or her
expenses in connection with his defense, provided that he or she undertakes to repay all amounts advanced if it is ultimately
determined that he or she is not entitled to be indemnified by the registrant.
In
addition, the registrant maintains standard policies of insurance under which coverage is provided to the registrant’s directors
and officers against losses arising from claims made by reason of breach of duty or other wrongful act, and to the registrant
with respect to payments which may be made by the registrant to such directors and officers pursuant to the above indemnification
provisions or otherwise as a matter of law.
Item
15. Recent Sales of Unregistered Securities.
None.
Item
16. Exhibits.
Exhibit |
|
|
No. |
|
Description |
3.1 |
|
Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020) |
3.2 |
|
Amendment to Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on July 29, 2022) |
3.3 |
|
Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020) |
3.4 |
|
Amendment No. 2 to Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on January 20, 2023) |
4.1* |
|
Form of Subscription Rights Certificate |
5.1* |
|
Opinion of Baker & Hostetler LLP |
10.1*† |
|
Collaboration and License Agreement dated December 5, 2022 by and between Akeso, Inc. and its affiliates and Summit Therapeutics Sub, Inc. |
23.1** |
|
Consent of PricewaterhouseCoopers LLP, a Delaware limited liability partnership, and independent registered public accounting firm for the Registrant. |
23.2** |
|
Consent of PricewaterhouseCoopers LLP, a United Kingdom entity, and independent registered public accounting firm for the Registrant. |
23.3* |
|
Consent of Baker & Hostetler LLP (included in Exhibit 5.1 hereto) |
24.1* |
|
Powers of Attorney (included on signature page hereto) |
99.1* |
|
Form of Instructions As To Use of Non-Transferable Subscription Rights Certificates |
99.2* |
|
Form of Letter to Stockholders who are Record Holders |
99.3* |
|
Form of Letter to Brokers and other Nominee Holders |
99.4* |
|
Form of Letter to Clients of Brokers and other Nominee Holders |
99.5* |
|
Form of Nominee Holder Certification |
99.6* |
|
Form of Beneficial Owner Election Form |
107* |
|
Filing fee table |
* |
Previously filed. |
** |
Filed herewith. |
† |
Portions of this exhibit have been omitted in
compliance with Regulation S-K Item 601(b)(10)(iv) because the Registrant has determined that the information
is not material and is the type that the Registrant treats as private or confidential. |
Item
17. Undertakings.
The
undersigned registrant hereby undertakes:
(1) To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i) to
include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) to
reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b)
if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering
price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
(iii) to
include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement; provided, however, that: Paragraphs (a)(1)(i), (a)(1)(ii)
and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d)
of the Exchange Act, that are incorporated by reference in the registration statement, or is contained in a form of prospectus
filed pursuant to Rule 424(b) that is part of the registration statement.
(2) That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.
(3) To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at
the termination of the offering.
(4) That,
for the purpose of determining liability under the Securities Act to any purchaser:
(i) Each
prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the
date the filed prospectus was deemed part of and included in the registration statement; and
(ii) Each
prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on
Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information
required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of
the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of
securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any
person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement
relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by
reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with
a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
(5) That,
for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant
pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if
the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant
will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
(i) Any
preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
424;
(ii) Any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to
by the undersigned registrant;
(iii) The
portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and
(iv) Any
other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
(6) That,
for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report
pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee
benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference
in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(7) Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion
of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of
1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the
payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the
securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy
as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.
(8) That,
for the purposes of determining any liability under the Securities Act of 1933:
(i) The
information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained
in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be
deemed to be part of this registration statement as of the time it was declared effective.
(ii) Each
post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of Menlo Park, State of California, on January 20, 2023.
|
SUMMIT THERAPEUTICS INC. |
|
|
|
|
|
|
By: |
/s/
Robert W. Duggan
|
|
|
|
Name: Robert W.
Duggan |
|
|
|
Title: Chief Executive
Officer; Executive Chairman |
|
Pursuant
to the requirements of the Securities Act of 1933, as amended, the following persons in the capacities indicated have signed this
Registration Statement below on the 20th day of January, 2023.
|
|
|
|
Signature
|
|
Title
|
|
|
|
|
|
/s/
Robert W. Duggan
Robert
W. Duggan
|
|
Chief Executive
Officer; Executive Chairman
(Principal Executive Officer) |
|
|
|
|
|
/s/
Ankur Dhingra
Ankur
Dhingra
|
|
Chief Financial
Officer (Principal Financial and Accounting Officer) |
|
|
|
|
|
/s/
Dr. Mahkam Zanganeh
Dr.
Mahkam Zanganeh
|
|
Co-Chief Executive
Officer and President, Director |
|
|
|
|
|
*
Kenneth
A. Clark
|
|
Director |
|
|
|
|
|
*
Dr.
Robert Booth
|
|
Director |
|
|
|
|
|
*
Ujwala
Mahatme
|
|
Director |
|
|
|
|
|
*
Manmeet
S. Soni
|
|
Director |
|
|
|
|
|
* |
|
Director
|
|
Dr.
Alessandra Cesano |
|
|
|
|
|
Director |
Dr. Yu Xia |
|
|
|
*
By: /s/ Ankur Dhingra |
|
Ankur Dhingra |
|
As Attorney-in-Fact |
|
|
|